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CHAPTER 1: INTRODUCTION
1.1 Obesity and Cancer
1.1a Obesity: A Global Pandemic
Obesity is “ a condition characterized by the excessive accumulation and storage of
fat in the body.” [1, 2]. This excess storage of fat is due to an imbalance between caloric
intake and energy expenditure, influenced by both modifiable and genetic risk factors
[3]. Obesity is clinically defined on a population-based level by body mass index (BMI),
an index that accounts for a patient’s height and weight (kg/m2). Patients with a BMI
greater than or equal to 30 are considered clinically obese, and between 25-30 are
considered overweight [3]. This system of clinically defining obese patients has been
used in research to uncover many disease associated risks factors [4-11].
In the last 25 years, the prevalence of obesity has doubled worldwide, leading to
nearly one-third of adults being considered overweight or obese in 70 countries [12].
The escalating obesity pandemic is particularly concerning because obesity is a known
risk factor for an array of chronic, debilitating or life-threatening diseases [4-11]; such as
rheumatoid arthritis, type 2 diabetes mellitus, cardiovascular disease, and cancer.
Underpinning the risk association between obesity and these diseases is the
accumulation of excess adipose tissue that elicits an aberrant innate immune response
causing local and systemic, chronic inflammation [13-19]. This activation of proinflammatory signaling is associated with an increase in infiltrated immune cells and
shift in phenotype within the adipose tissue. Importantly M2 polarized macrophages
contribute significantly to the production of pro-inflammatory cytokines including
interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) in the adipose tissue of
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obese individuals [20, 21], which can in turn lead to the aberrant production of free
radicals, including reactive oxygen species (ROS), both of which are hallmarks of
obesity [22].
1.1b Obesity and Cancer Risk
Cancer is a disease defined by an abnormal growth of cells within an organ,
leading to the formation of a tumor or mass, which can invade surrounding tissues or
colonize distant tissues in a process referred to as metastasis; the principal cause of a
cancer-related death. Presently, cancer is the second leading cause of death in the US,
and recent reports have raised awareness that the number of cancer cases associated
with obesity is substantial and increasing [23-25], and obesity-related cancers in
younger female patients are also more frequently occurring [12, 25].
1.1c Obesity-associated TNBC Risk
Contributing to this burden is the association between obesity and breast cancer
(BCa), the most common cancer in women [26]. However, most epidemiological studies
to date, which have associated risk of obesity with BCa, failed to stratify patients by
histological subtype [27]. In recent years there have been a series of epidemiological
studies published that assess risk in patient populations stratified by histological
subtype, including human epidermal growth factor receptor 2 (HER2) positivity in their
analysis, which has uncovered an association in pre-menopausal women between
obesity (BMI >30) and hormone/HER2 receptor negative cancer, also known as Triple
Negative Breast Cancer (TNBC) [4-10, 28-33]. These studies report that obesity is a risk
factor for TNBC diagnosis and worse cancer-associated outcomes [4-10, 28-32].
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Poorer outcomes associated with TNBC, are in part due to the lack of therapeutic
options available. As TNBC tumor cancer cells lack expression of estrogen receptor
alpha (ERα), progesterone receptor (PR), and the HER2 oncogene, none of the
currently available molecularly targeted therapeutics, used in the treatment of other BCa
subsets, are used to treat TNBC patients. Overall, TNBC patients tend to have a poorer
prognosis, including higher probability of both metastasis and recurrence, after initial
response to chemotherapeutic treatment [34-40]. Understanding how obesity might
influence the biology of this BCa subtype also has the potential to uncover novel and
more context dependent drug targets.
Pre-menopausal African American (AA) women, whom are more likely to develop
TNBC [38, 41-45], are also more likely to be obese in the US [21, 46]. Moreover, there
is evidence that AA women with TNBC have worse overall survival than European
American (EA) women [21]. Studying the effects of obesity on tumor biology could be an
important way to improve our understanding of racial disparities in TNBC incidence and
outcomes, which persist.
1.1d Mechanisms Driving Obesity-associated TNBC
The association between obesity and diagnosis of ERα positive, hormonedependent BCa in post-menopausal patients, was recognized early [47]. A prevailing
idea regarding the molecular mechanism is that ERα-positive cancer in postmenopausal women is fueled by estrogens that are synthesized by adipose tissue in
response to inflammatory signaling factors [48]. TNBCs are hormone-independent, thus
the past prevailing idea regarding adipose tissue derived estrogens, as a mechanism
driving obesity-associated risk, is irrelevant.
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Several hormone-independent features of obesity have been associated with
promoting obesity-associated cancers and TNBC, including hyperinsulinemia, fatty acid
metabolism, and circulating and local production of cytokines and adipokines, which
results in increased ROS production [18, 19, 21]. Some important signaling factors
include insulin, glucose, leptin, IL-6 and adiponectin. Many of these signaling factors
and their requisite pathways have been studied extensively in cancer, and act as tumor
growth promoters [19, 21]. Leptin, insulin signaling and others have also been linked to
cancer stem cell-like cells (CSCs), and expression of pluripotency transcription factors
[49-57]. Whether, the mechanism downstream of these signaling factors, which actually
promotes CSCs, are related to obesity-associated risk, remains unclear.
1.2 CSCs
1.2a Defining CSCs
CSCs represent a small subpopulation of less differentiated cancer cells found
within TNBC tumors, as well as patient-derived cell cultures, which may represent as
little as 0.05-1% of total cells within a tumor [58-81]. The CSC sub-population of cells
have unique characteristics, as compared to other cells within a tumor, including their
ability to self-renew, asymmetrically divide, initiate tumors in mice, resist effects of drug
treatment, and remain quiescent [63-70, 73-78, 80, 81]. Normal adult stem cells,
including mammary stem cells, have some of these characteristics, such as asymmetric
division, self-renewal capacity, and quiescence. However, CSCs are distinctly tumor
cells, and the origin of CSCs remains unclear [82, 83]. Though how adult stem cells and
CSCs are regulated could be very similar [83].
1.2b Role in Cancer
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One of the major rate-limiting steps in the formation of a distant metastasis is
colonization of disseminated tumor cells, as less than 0.1% of cells may actually seed
and subsequently have the ability to form macrometastases in a non-native tissue or
organ [84]. Several studies have shown that disseminated BCa cells capable of
overcoming these odds tend to have characteristics of CSCs [63-66], and CSC
enrichment is associated with clinical cancer metastasis [58-62, 64, 67-71] and also
obesity [49-57]. Moreover, there is an overwhelming body of evidence showing that
obesity is associated with features linked to worse outcomes including: higher grade
tumors, distant metastasis, shorter disease-free survival and greater risk of mortality
[85], with metastasis being the primary complication associated with cancer-related
death. Finally, TNBC patients have also been shown to have higher abundance of
CSCs, linked with worse outcomes [58-62], emphasizing the importance of studying
CSCs in this particular subtype of BCa.
1.2c Experimental Models for Studying CSCs
CSCs can be identified and studied in vitro using an enrichment assay, such as a
mammosphere or prostasphere assay. In this assay, bulk populations of cells are plated
in non-adherent, serum-free conditions, and CSCs are selected for by growing over a
set period of time [57, 86, 87]. This assay measures self-renewal capacity by providing
a crude estimate of the number of cells in a cultured population, which have the
capacity to survive and self-renew.
Cell surface markers are used to sort and identify CSCs via flow cytometry, and
further test the molecular characteristics and drug sensitivity of CSCs in vitro, and are
also used to identify CSCs in patient tumors [67, 88-91]. However, defined sets of cell
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surface markers have not yet been established for TNBC, and the percentage of cells
deemed stem-like are conflicting between these studies. These assays measure the
presence of CSCs in culture and in tumor tissues, or their self-renewal capacity.
Given that CSCs are known to have metastatic potential and are associated with
clinical cancer metastasis [64, 67-71], their ability to form tumors in vivo is an important
defining feature. Thus the current gold standard for studying the presence of CSCs in a
bulk population is by performing a tumor propagating experiment [87, 90, 92], first
described in 1997 in acute myeloid leukemia [93]. Examining the tumorigenicity of a
bulk population of cells at low cell titers, after inoculation in an immune compromised
mouse tumor model, is performed to test for presence of CSCs; as it has been shown
that CSCs are characteristically tumor initiating. Using this assay, cells can be
genetically manipulated or treated with drugs before or after inoculation in mice, in order
to test changes in tumorigenicity compared to a known control group.
1.2d Clinical Relevance of Studying CSCs
Targeting CSCs is thought to be crucial in overcoming resistance to
chemotherapy, and preventing further development of metastatic disease. As described
above, it is well established that the process of metastasis occurs early after
tumorigenesis, and that the rate-limiting step to the formation of overt metastasis, is the
ability of a circulating tumor cell to seed at a distant site; of which CSCs play a distinct
role. Therapeutic targeting of the CSC population therefore has the potential to inhibit
further growth of seeded tumor cells at metastatic sites. TNBC patients tend to have
positive initial responses to chemotherapeutic treatment, but have higher probability of
both metastasis and recurrence, contributing to poorer outcomes [34-40]. Identification
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of targetable CSC driver genes will be crucial for improving TNBC outcomes, by
preventing metastatic tumor growth.
1.2e ROS and CSCs
One well understood characteristic of obesity is systemic induction of chronic
inflammation [94, 95]; specifically the accumulation of adipose tissue in obese patients
triggers innate immune responses, which in turn leads to aberrant production of ROS,
as stated above [22, 96-99].
ROS plays an important role in normal stem cell biology, impacting self-renewal
and differentiation in a dose-dependent manner. Stem cells are also more sensitive to
ROS levels than their asymmetrically produced progeny, and have developed
mechanisms for surviving in the presence of ROS [100]. Alterations in ROS production
are also a known hallmark of cancer cells, of which upregulated ROS production has
been shown to promote CSCs, and trigger alterations in antioxidant enzyme activity
[100].
Antioxidants, which maintain the cellular balance of ROS to prevent damage and
maintain necessary redox signaling, have less intrinsic activity in obese individuals
[101], whom have enrichment of CSCs. In particular, catalase, an H2O2 neutralizing
enzyme, has less activity in obese patients [20]. Our lab has shown that treatment with
either genetically engineered catalase or (-) epicatechin, which reduces cellular H2O2
and thus perturb the redox state of the cell, inhibits survival and self-renewal capacity of
TNBC cell line-derived CSCs [57].
Findings, including ours, also demonstrate that ROS is an important driver of
TNBC CSCs [57, 102] and malignant BCa cell transformation [103]. For example,
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normal mammary epithelial cells have nearly undetectable levels of ROS in culture,
versus HER2 expressing cells, which have higher ROS levels and induced HIF1α
signaling [103]. Moreover, we find that TNBC cells have higher intracellular levels of
ROS, compared to normal breast epithelial cells [57].
ROS species, such as H2O2, can act as signaling molecules to modulate
homeostatic redox levels by impacting protein function and gene expression in normal
stem cells, which are particularly sensitive to oxidative stress [100]. In our studies, in a
time course microarray analysis, comparing antioxidant treated versus untreated TNBC
cells, we identified a gene whose expression was ROS-dependent and crucial for CSC
maintenance and expansion in TNBC cell cultures [57]. This gene was an epigenetic
reader protein called methyl-CpG-binding domain protein 2 (MBD2), specifically the
MBD2 mRNA transcript variant 2 (MBD2_v2). Further analysis of this gene in TNBC cell
lines revealed that MBD2_v2 expression was higher in CSCs in cell culture, as
compared to bulk cancer cells, and that overexpression of MBD2_v2 was capable of
promoting CSC formation in in vitro sphere formation assays. These data suggested
that ROS-dependent expression of MBD2_v2 was important for promoting TNBC CSC
self-renewal capacity in vitro.
1.3 MBD2
1.3a MBD2 Splice Variants
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MBD2 was first identified in 1998 by Hendrich and Bird, as part of a nuclear
family of methyl binding domain (MBD) containing proteins [104]. Post-transcriptionally,
MBD2 mRNA is alternatively spliced yielding two mRNA spliced variants, which differ in
the C-terminal end of each resulting protein (Fig. 1) [104]. The longest MBD2 gene
product, MBD2 transcript variant 1 (MBD2_v1), has 3 main domains, an N-terminal
glycine/arginine rich region, an internal MBD, and a c-terminal transcriptional repressor
domain (TRD) encoded by exons 4-7. MBD2 binds methylated CpG sites through an
electrostatic interaction, where two arginine residues within the MBD form hydrogen
bonds with guanines surrounding methylated cytosines (5-mc), which stabilizes the
central β-sheet within that region and leaves the outer N-terminal and C-terminal
domains mobile [105, 106]. An intrinsically disordered region also exists within the TRD,
which kinetically enhances the affinity of MBD2 for methylated CpG residues [104, 107].
After binding a methylated CpG site, MBD2 recruits the nucleosome remodeling
deacetylase (NURD) complex through its C-terminal TRD domain to repress RNA
transcription at sites of dense 5-mc [108-111]. MBD2_v1 is classically known to bind

Figure 1. Graphical representation of MBD2 gene coding exons
(E1-E8), along with structural domains of alternatively spliced mRNA
variant species 1 and 2 derived from the MBD2 gene transcript and
their translated protein lengths. MBD=methyl binding domain;
IDR=intrinsically disordered region; CC=coiled-coil domain. (Bao et
al, 2017).
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hypermethylated CpG sites in DNA promoter regions to inhibit RNA transcription of
target genes, which is also thought to promote differentiation in the context of human
pluripotent stem cells (hPSCs) [104, 107, 112]. However, studies have shown that
knockdown (KD) of MBD2 gene products, non-specifically targeting both transcript
variants, leads to both up and downregulation of global gene expression; and more
intriguingly MBD2 is less frequently bound to DNA regions near epigenetic marks
associated with active transcription [108-111], which directly opposes known repressive
functions.
MBD2_v2, also known as the testis-specific isoform, is spliced by the serine and
arginine rich splicing factor 2 (SRSF2) in hPSCs [112]. Studies in hPSCs show that the
SRSF2 splicing factor binds MBD2 pre-mRNA at the exon 2-3 junction, and promotes
alternative splicing of the MBD2_v2 mRNA [112]. MBD2_v2 is particularly unusual as it
lacks the TRD, but retains a short unique exon of unknown function at its c-terminus.
This structural difference renders MBD2_v2 putatively unable to bind and recruit
transcriptional repressors, such as the NURD complex.
MBD2 has been shown to bind several pluripotency transcription factor
promoters including the POU class 5 homeobox 1 (OCT4), Nanog homeobox (NANOG),
and SRY-box 2 (SOX2) genes in hPSCs, which were actively being transcribed [104,
112]. This interaction has been shown to be important in maintaining pluripotency of
hPSCs [112].
1.3b MBD2_v2 Function
The normal molecular function of the MBD2_v2 splice variant in any type of
terminally differentiated or adult progenitor cell is largely unknown. The only known
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function of MBD2_v2 is in promoting pluripotency of hPSCs and promoting
reprogramming of induced pluripotent stem cells [112]; as well as in our study which
shows that MBD2_v2 plays a distinct functional role in maintaining self-renewal capacity
of TNBC CSCs [57].
In TNBC whole cell lysates we have found that MBD2_v1 protein and mRNA are
expressed at a significantly higher level than MBD2_v2 [57]. We also find that
expression of MBD2_v2 is exclusively higher than MBD2_v1 in CSCs, versus bulk
TNBC cell populations [57]. Together these data suggests that MBD2_v2 expression is
functionally important in the TNBC CSC sub-population.
1.4 Relationship between TNBC and Obesity-associated PCa
Although women appear to bear more of the burden of cancers attributable to
obesity, men are not invulnerable. Prostate Cancer (PCa), which is the second leading
cause of cancer-related death among men, similar to TNBC has also been shown to be
associated with obesity-related risk and high-grade PCa disease [113-116].
High-grade PCa and TNBC are similar in that they disparately impact AAs. AA
women tend to have higher incidence of TNBC [38, 41-45]. Similarly AA men (AAM)
have been shown to have both a higher rate of PCa incidence and a two-fold to five-fold
greater risk of PCa-related mortality, compared to EA men (EAM) [117]. These
disparities could reflect higher rates of obesity reported in AA populations [46].
Obesity-associated risk factors, including higher fat content diets, higher BMI
[118, 119], and higher rates of hypertension are reported in AA PCa patients. However,
the relationship between race and disease burden remains to be fully understood, and
the cause is likely multifaceted, including undetermined contributions from ancestry
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genetics and life-style risk factors [120-124]. Though improvements in PCa detection,
access to care, and survival across all demographics have been made, PCa race
disparities still continue [117, 125, 126], and AAM diagnosed with low-risk PCa are
more likely to intrinsically harbor high risk disease [127].
We have shown that PCa tumors from AAM have upregulation of inflammatoryrelated genes [128], such as IL-6 and nuclear factor kappa B (NFκB), both of which
have been associated with obesity-related cancers [19]. Given that pro-inflammatory
signaling is an important feature of obesity [13-19], we hypothesized that these data
might reflect an underlying molecular difference in an obese phenotype, between AAM
and EAM.

Determining how obesity and inflammatory-related signaling affects the

molecular biology of PCa could reveal important molecular targets for high-grade AAM
PCa patients, whom currently are limited in their therapeutic options.
In this study, we extend our work from TNBC to PCa, given the similarities in
racial disparities and obesity-related risk, and demonstrate the importance of MBD2_v2
in driving PCa CSCs, linked to pro-inflammatory IL-6 signaling.
1.5 Hypothesis
Obesity represents a distinct health-related state, which disproportionately
impacts TNBC and high-risk PCa patient populations. The escalating obesity pandemic
is particularly concerning because obesity is a known risk factor for an array of chronic,
debilitating or life-threatening diseases [4-11]. Obesity impacts health by generating
significant redox imbalance driven by pro-inflammatory cytokine signaling.
The central hypothesis of my dissertation work is that ROS-dependent MBD2_v2
expression is a key molecular feature driving TNBC and high-risk PCa incidence and
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recurrence due to its ability to maintain and promote expansion of tumor-initiating CSCs.
Considering that obesity is coupled with inflammation [129, 130], we also hypothesize
that obesity might fuel this mechanism to increase MBD2_v2 expression and in turn
enhance the tumor-initiating CSC phenotype (Fig. 2).
This study sought to better understand how MBD2_v2 is regulated in CSCs and
whether obesity or obesity-related inflammatory signaling plays a role in increasing
expression of MBD2_v2 in TNBC and PCa cells to promote the CSC phenotype, which
could explain some of the racial disparities that currently exist in these patient
populations.

Obesity

• Risk factor for
TNBC
• ñ Increased
inflammation and
ROS (oxidative
stress)

MBD2_v2

• ROS-regulated
• High expression
in TNBC CSCs
• Promotes TNBC
CSCs

Hypothesis

Obesity promotes
growth of TNBC
CSCs via
MBD2_v2

Figure 2. Graphical representation of hypothesis, describing that obesity, which
is associated with ROS production promoted by chronic inflammation, drives
TNBC CSCs through upregulation of MBD2_v2 expression.
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CHAPTER 2: OBESITY PROMOTES EXPRESSION OF MBD2_V2 IN TUMOINITATING TNBC CELLS
The data presented in this chapter were published on January 19th, 2019 in the
journal Molecular Oncology [131].
2.1 Preface
All mouse model experiments were performed in collaboration with Dr. Lisa
Polin at the Karmanos Cancer Institute (KCI) Animal Model and Therapeutics
Evaluation Core facility. Dr. Kristen S. Purrington at the KCI Population Sciences
Department was generous in providing the human microarray data. Statistical
analyses were performed in collaboration with Dr. Gregory Dyson at the KCI
Biostatistics core.
2.2 Introduction
In the last 25 years the prevalence of obesity has doubled in 70 countries,
including the United States, and nearly one-third of adults worldwide are now
overweight or obese [12]. The rising obesity pandemic is decidedly concerning because
obesity is a known risk factor for an array of chronic, debilitating or life-threatening
diseases [11], such as rheumatoid arthritis, type 2 diabetes mellitus, cardiovascular
disease, and cancer [11]. Underpinning the risk association between obesity and these
diseases is the accumulation of excess adipose tissue that elicits an aberrant innate
immune response causing local and systemic chronic inflammation, the hallmarks of
which include increased pro-inflammatory cytokine levels yielding increased production
of free radicals, including ROS [13-15, 130].
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The number of cancer cases worldwide attributable to obesity is substantial and
increasing [23, 25, 132]. It is becoming more common for younger individuals to be
diagnosed with obesity-related cancers [25], and women bear a greater burden than
men [12, 25]. Contributing to this burden is the association between obesity and BCa,
the most common cancer in women [26]. The association for obesity and diagnosis of
ERα positive, hormone-dependent BCa in post-menopausal patients was recognized
early [47]. A prevailing idea regarding the molecular mechanism is that ERα-positive
cancer in post-menopausal women is fueled by estrogens that are synthesized by
adipose tissue in response to inflammatory signaling factors [48]. More recent
epidemiological studies report that obesity is a risk factor for TNBC diagnosis [4-10],
and worse cancer-associated outcomes [28-32]. A TNBC diagnosis means that the
tumor cancer cells lack expression of ER!, PR and the HER2 oncogene, a member of
the epidermal growth factor family of receptor tyrosine kinases. Based on collective
evidence that obesity-induced chronic inflammation is a common factor promoting other
diseases, we reasoned that inflammation also serves as the general link between
obesity and TNBC. However, the exact molecular mechanism remains unknown.
We previously identified that ROS-dependent expression of epigenetic reader
MBD2, specifically the alternative mRNA splicing variant MBD2_v2, is crucial for
maintenance and expansion of self-renewing CSCs in TNBC cell cultures [57].
Moreover, in heterogeneous cultures MBD2_v2 expression is contained in the CSC
fraction [57]. The relevance of CSCs is that they are a subpopulation of cancer cells
recognized as the source of malignant tumor initiation [73-75], and they give rise to drug
resistance and metastatic recurrence [65, 76-78]. Due to its function to maintain and
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promote expansion of tumor-initiating CSCs, ROS-dependent MBD2_v2 may be a key
molecular feature driving TNBC incidence and recurrence. Considering that obesity is
coupled with inflammation and ROS [130], we hypothesized that obesity can fuel an
increase in MBD2_v2 expression to promote the tumor-initiating CSC phenotype in
TNBC cells, setting a course to understanding why obesity is a risk factor for TNBC
diagnosis and poor outcomes. Here, we report analysis of patient specimens and in vivo
data supporting our hypothesis. Also, it was previously reported that SRSF2 is
necessary for expression of MBD2_v2 in hPSCs [112]. We present new mechanistic
evidence that ROS-dependent expression of SRSF2 drives TNBC MBD2_v2 expression
and tumor-initiating CSCs.
2.3 Results
2.3.1 Associations between tumor MBD2_v2 expression and patient outcomes
and BMI
We hypothesized that obesity can cause an increase in MBD2_v2 expression to
promote the tumor-initiating CSC phenotype in TNBC cells, setting a course to
understanding why obesity is a risk factor for TNBC diagnosis and poor outcomes. To
establish the plausibility of our hypothesis it was a priority to address the question: Do
MBD2_v2 levels in TNBC patient tumor specimens associate with survival outcomes
and BMI? Analysis using the KM Plotter database [133], testing for associations
between gene transcript levels and relapse-free survival (RFS) among 246 specimens,
showed that high expression of MBD2_v2 in TNBC patient tumors associates with high
rates of relapse (Hazard ratio (HR)= 1.66, P = 0.05, Fig. 1A). The KM Plotter database
lacks BMI data. To test for a relationship between patient BMI and tumor transcript
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expression we used another existing probe-based gene expression dataset comprising
59 TNBC specimens with known BMI status collected at KCI Detroit, MI (Table S1).
Linear regression analysis indicated that there is a positive association for MBD2_v2
expression and BMI (P = 0.04, correlation 0.27, Fig. 1B), and MBD2_v2 expression
levels are significantly increased in tumors from patients with BMI ≥ 30 compared to
tumors from patients with BMI < 30 (P = 0.03, Fig. 1C). Based on similar analysis of
these data sets there is no association between tumor expression of the full-length
isoform MBD2_v1 and patient BMI, and high MBD2_v1 expression is associated with
low rates of relapse (Hazard ratio (HR)=0.68, P = 0.04, Fig. S2). The KCI dataset
currently lacks a sufficient number of events to test for associations with outcomes.
2.3.2 Increased tumor formation frequency and tumor MBD2_v2 expression in DIO
mice
We investigated if obesity causes increased TNBC cell tumor initiation capacity
and increased tumor MBD2_v2 expression using female B6.129S7-Rag1tm1Mom/J
(B6.Rag1-/-) mice as a model for diet-induced obesity (DIO). Due to a homozygous
Rag1 gene deletion this model lacks mature T and B lymphocytes [134]; therefore, it
can be used for human tumor xenograft and cancer cell implant studies [135-137]. The
B6.Rag1- / - model does, however, maintain macrophages with the capacity to
recapitulate the pro-inflammatory environment and oxidative stress induced by
increased adiposity [138]; and like its C57BL/6J background — the mouse strain most
commonly used to study cancer and obesity [139] — B6.Rag1-/- presents a DIO
phenotype that mimics human obesity [135, 137, 138, 140, 141]. We employed two
TNBC cell lines, MDA-MB-231 and MDA-MB-468, and began by assessing the impact
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of obesity on tumor formation rate. Groups of mice were randomly assigned either a
control purified diet (kcal%=10, gram%=4.3); or a matched formula calorie-dense, highfat diet (kcal%=60, gram%=35). As was reported previously for female C57BL/6J and
B6.Rag1-/- mice [137, 142], by day 35 the mice on the high-fat diet exhibited a
significant weight increase relative to control mice (P < 0.001, Fig. 2A). On day 36,
groups of DIO mice and lean controls were inoculated with MDA-MB-231 or MDA-MB468 cells. Mice were monitored for tumor formation up to 150 days post inoculation, and
tumor formation frequencies were calculated. Relative to control mice, the tumor
formation frequency for DIO mice was increased 2-fold for the MDA-MB-468 cell line
(Fig. 2B), and approximately 4-fold for the MDA-MB-231 cell line (P = 0.025, Fig. 2C).
The rates of MDA-MB-468 cell line tumor formation in each condition, control and DIO
mice, were greater than the rates for MDA-MB-231 cells. MDA-MB-468 cultures, prior to
inoculation, also expressed higher endogenous levels of MBD2_v2 relative to MDA-MB231 cells (Fig. S3).
These experiments were devised to compare tumor formation rates, but tumor
mass was plotted (Fig. 2D-E). The upward slopes of the growth curves are similar,
indicating that DIO had little or no effect on the growth rates of established MDA-MB468 or MDA-MB-231 tumors. We performed semi-quantitative RT-PCR analysis of
tumor MBD2_v2 expression. MBD2_v2 levels were higher in tumors harvested from
DIO mice compared to tumors harvested from control mice (P < 0.001, Fig. 2F).
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2.3.3 Increasing MBD2_v2 expression in TNBC cells increases tumor initiation
capacity
To more directly test if increased MBD2_v2 causes increased tumor initiation capacity
we stably overexpressed MBD2_v2 in TNBC cells prior to inoculation. We proceeded to
re-establish, as recently reported by us using other TNBC lines [57], that MBD2_v2
overexpression promotes expansion of the CSC fraction in MDA-MB-231 TNBC cell
cultures using a mammosphere formation assay. Stable overexpression of MBD2_v2 in
cells by lentiviral transduction, confirmed by immunoblot and semi-quantitative RT-PCR
analysis (Fig. 3A-B), caused a marked increase in the numbers of mammospheres that
grew from equal seeding under non-attachment serum-free culture conditions relative to
a stable green fluorescent protein (GFP) expressing MDA-MB-231 control cell line (Fig.
3C). We inoculated mice with MBD2_v2 overexpressing or GFP-expressing MDA-MB231 cells. By day 100, 6 of 6 mice inoculated with MBD2_v2 overexpressing MDA-MB231 cells bore tumors, yet at the same time only 1 of 6 mice carried tumors in the GFP
control group (Fig. 3D). The experiment was extended to 150 days post-inoculation; at
which point 3 of 6 mice remained tumor-free in the GFP control group (Fig. 3D). Tumor
mass was documented over the course of the experiment, and according to growth
curve plots MBD2_v2 overexpression did not affect the rate of tumor growth (Fig. S4).
This is consistent with the insight that MBD2_v2 promotes CSCs, which are not highly
proliferative [78].
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2.3.4 TNBC cell MBD2_v2 expression depends on antioxidant-sensitive SRSF2
expression
It is reported that splicing factor SRSF2 is necessary for expression of alternative
mRNA splicing variant MBD2_v2 in hPSCs [112]. We designed a set of experiments to
examine if the same regulatory relationship between SRSF2 and MBD2_v2 exists in
TNBC cells. First, we observed that expression of SRSF2 is, like MBD2_v2 [57], subject
to antioxidant-sensitive, ROS-regulation in TNBC cells. Using MDA-MB-468 and
SUM149 TNBC cell lines, which expressed similarly abundant endogenous levels of
SRSF2, (–)-epicatechin antioxidant treatment reduced ROS and MBD2_v2 levels (Fig.
S5), and downregulated SRSF2 mRNA and protein levels (Fig. 4A-B). We then
established two independent SRSF2 stable KD (using two unique short-hairpin RNA
(shRNA) sequences) and non-silencing vector control MDA-MB-468 cell lines. The KD
of SRSF2 resulted in decreased MBD2_v2 protein and mRNA levels (Fig. 4C-D).
According to mammosphere formation assays, SRSF2 KD also resulted in fewer
mammospheres (Fig. 4E), and a reduction in size of those that did survive (Fig. 4F).
Altogether, this characterizes a role for the ROS-dependent SRSF2–MBD2_v2
regulatory axis in TNBC cells.
2.3.5 Tumor SRSF2 expression is increased in DIO mice, and down-regulation of
SRSF2 hinders tumor initiation capacity of TNBC cells
We performed semi-quantitative RT-PCR analysis for SRSF2 expression in tumors
harvested from DIO and control mice. Like MBD2_v2 (Fig. 2F), SRSF2 levels were
consistently higher in tumors harvested from DIO mice (P < 0.001, Fig. 5A). To more
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directly assess if increased SRSF2 has a role in increased tumor initiation capacity, we
selected one of the stable KD cell lines (SRSF2 sh2) to test if down-regulating SRSF2
yields decreased tumor initiation capacity in the high tumorigenic context of MDA-MB468 cells in DIO mice. SRSF2 KD cells demonstrated significantly delayed tumor
initiation relative to non-silencing control cells (P < 0.05, Fig. 5B). By day 24 post
inoculation, tumors were formed in 100% of mice inoculated with non-silencing control
cells (6 of 6), and at the same time point only 33% of mice (2 of 6) bore tumors in the
SRSF2 KD group (Fig 5B). Tumor mass was also documented over the course of the
experiment, and there was no significant difference in growth rates comparing SRSF2
KD and control tumors (Fig. S6). This remains consistent with insight that SRSF2–
MBD2_v2 promotes CSCs, which are not highly proliferative [78]. According to semiquantitative RT-PCR analysis SRSF2 KD was lost in established tumors (Fig. S6). In
addition, high expression of SRSF2 in TNBC patient tumors associates with high rates
of relapse (Hazard ratio (HR) = 1.57, P = 0.04, KM Plotter database, Fig. 5C). However,
analysis of the KCI dataset, which revealed an association between MBD2_v2 and BMI
(Fig. 1b and 1c), failed to identify an association between SRSF2 expression and BMI
(Fig. S6).
2.4 Discussion
TNBC is a molecular subtype that accounts for 15% of invasive BCa diagnoses
[143, 144]. Incidence rates in developing countries and among women of African
ancestry are higher [143, 144]. TNBC is also more prevalent in younger, premenopausal women [38, 145], and obesity is a risk factor for TNBC diagnosis [4-10],
and worse cancer-associated outcomes [28-32]. Ultimately, women diagnosed with
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TNBC have the lowest 5-year survival rates among all BCa patients, in large part due to
a lack of therapeutic options [146]. For TNBC the molecular drivers remain uncertain
and targeted therapies do not exist. Moreover, development of transformative treatment
strategies for TNBC must first identify and then find a way to target factors driving the
tumor-initiating CSCs, which also give rise to drug resistance and metastatic recurrence
[32, 76-78]. These clinical challenges further underscore the value of our investigation.
Based on a review of the literature, we have generated the earliest reports on the
role of epigenetic reader and alternative mRNA splicing variant MBD2_v2 to sustain and
promote the tumor-initiating CSC phenotype; first based on studies conducted in
vitro [57, 147], and now based on in vivo experiments that link it to obesity. The results
herein also elucidate that splicing factor SRSF2 is necessary for expression of
MBD2_v2 in TNBC cells and for CSC survival. Moreover, SRSF2 and MBD2_v2
expression in TNBC cells is dependent on antioxidant-sensitive ROS. We investigated if
obesity impacts SRSF2 and MBD2_v2 by inoculating a DIO mouse model with tumorforming TNBC cell lines, and in agreement with our hypothesis SRSF2 and MBD2_v2
expression levels were significantly upregulated in tumors harvested from DIO mice
displaying increased tumor formation rates. The DIO mice readily exhibited increased
visceral adiposity and we verified that systemic oxidative stress levels were increased in
DIO mice relative to control mice by measuring liver malondialdehyde, a lipid
peroxidation marker [148] (Fig. S7); but a possible shortcoming of our study is that we
did not attempt to treat DIO mice systemically with (–)-epicatechin antioxidant in order to
affirm that inflammation, ROS specifically, was regulating increased SRSF2 and
MBD2_v2 expression in TNBC cell line-derived tumors as in TNBC cell line cultures

23
(Fig.4A) [57]. However, it is well-documented in the literature that dysfunctional adipose
tissue and resident macrophages function as an endocrine organ, producing proinflammatory cytokines that directly act on tumors [17], and more detailed insights for
how the B6.Rag1-/- DIO mouse model system likely parallels human physiology in this
regard came to light when we applied genome-wide analysis to evaluate the greater
impact of DIO on TNBC tumor gene expression. The significant results highlighted
evidence of the effects of pro-inflammatory cytokines, specifically interferon gamma
(IFNγ) signaling (Fig. S7). Circulating IFNγ is produced by adipocytes in obese
individuals and IFNγ levels are elevated by DIO in B6.Rag1- / - mice [149, 150].
Activation of BCa cell IFNγ receptors increases ROS levels, specifically hydrogen
peroxide [151]. Also in obese BCa patients, increased macrophage infiltration of breast
adipose tissue yields additional paracrine-acting pro-inflammatory cytokines [152].
For experiments designed to more directly assess if increased expression of
MBD2_v2 and SRSF2 play a causative role in increased tumor formation, we stably
modified the levels of MBD2_v2 or SRSF2 in TNBC cells prior to inoculation. MBD2_v2
overexpression significantly increased tumor initiation capacity of TNBC cells in lean
mice; and SRSF2 KD, which decreased MBD2_v2 expression, significantly hindered
tumor formation capacity in the more tumorigenic context of DIO mice. The relevance of
the experimental methodology to inoculate mice with cancer cells to measure efficiency
of tumor formation, or tumorigenicity, was previously established [90]. Researchers
observed that relatively small numbers of cells exhibiting the CSC phenotype possess
the capacity to macro-colonize and subsequently form tumors in mice; but greater
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numbers of cells with alternate phenotypes, referred to as bulk cancer cells, fail to
macro-colonize [90].
The in vitro and in vivo experimental data presented here support that the
SRSF2–MBD2_v2 regulatory axis is a feature necessary for maintenance of TNBC
tumor-initiating CSCs that can be induced to expand the CSC fraction (Fig. 6).
Therefore, SRSF2–MBD2_v2 expression would not be exclusive to, but increased in
TNBC tumors from obese patients and patients with poor survival outcomes. Results
from our analysis of patient tumor sample data are in-line with this idea. KM plotter
database inquiries revealed that high mRNA expression of MBD2_v2 and SRSF2 in
TNBC specimens associates with high rates of relapse. MBD2_v2 levels also positively
associate with BMI and are significantly higher in tumors from obese women; however,
the same dataset did not show an association for SRSF2 and BMI. This does not
necessarily contradict our mechanistic evidence that MBD2_v2 expression in TNBC
cells depends on SRSF2; it may reflect that differences in SRSF2 mRNA levels are
small and challenging to discern in analysis of RNA from patient formalin-fixed paraffinembedded (FFPE) cancer specimens. This rationale is in-line with results from our
analysis of tumors harvested from DIO mice relative to lean controls: SRSF2 expression
was increased 4-fold in DIO tumors and its target, MBD2_v2 expression, was increased
20-fold.
The function of MBD2_v2 to regulate TNBC CSCs is underscored by the
necessity for MBD2_v2 to maintain the self-renewing capacity of hPSCs [112]. A report
by Lu et al. details the mechanism whereby MBD2_v2 activates essential hPSC factors
such as NANOG [112]. We also observed that increasing MBD2_v2 upregulates stem
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cell marker NANOG expression in TNBC cells, and NANOG levels are increased in
tumors harvested from DIO mice relative to tumors from control mice (Fig. S8). NANOG
expression is detected in normal mammary stem cells, and decreases upon
differentiation. Furthermore, NANOG expression is associated with high-grade TNBC
and worse patient outcomes [153]. The strong association between NANOG expression,
high-grade TNBC and worse outcomes is likely directly related to its CSC-specific
expression [78], and CSC enrichment is associated with obesity [49-57]. Our data
reinforce that obesity promotes CSCs, through activation MBD2_v2, which similar to
embryonic stem cells (ESCs), regulates pluripotency transcription factor expression to
drive self-renewal capacity.
Moving forward, we will continue work to elucidate the mechanistic pathway
leading to aberrant, upregulated MBD2_v2 expression dependent on ROS and likely
subject to inflammation related to obesity. Another priority is to study if SRSF2 and
MBD2_v2 play a role in malignant transformation of partly transformed or noncancerous
breast epithelial cells, and if this too may be induced by obesity. It is notable that the
dataset used to uncover the positive association between MBD2_v2 expression and
BMI consists entirely of specimens from African American women. African American
women are approximately 2 times more often obese relative to EA women [154] and a
TNBC driver mechanism fueled by obesity could contribute to the worse TNBC
outcomes and higher incidence of TNBC among African American women [124, 143].
We expect the association between MBD2_v2 and BMI to be similar irrespective of
race, yet it is possible that planned analysis of tumors from EA women will not so readily
demonstrate the association. Conversely, lifestyle factors contributing to systemic
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inflammation independent of obesity such as sleep deprivation and psychosocial stress
are also more prominent in African Americans [155-158]; and inflammation in nonobese patients may influence the SRSF2-MBD2_v2 axis and be a confounding variable
for the association between obesity and MBD2_v2 expression in tumors from African
American women. Either way, our study provides a new avenue for research to
understand the molecular biology of race-associated TNBC disparities.
Finally, in our retrospective analysis of MBD2_v2 expression in patient tumor
data we used the threshold BMI ≥ 30kg/m2 to define obesity [11]. Obesity is a medical
condition that applies to overweight individuals with excess visceral adiposity [11]. While
it is applicable to estimate obesity in the general population, a BMI calculation does not
measure adipose tissue, nor does it inform an individual of their body fat distribution.
Calculating the waist-to-hip ratio or more directly measuring body fat percentage are
likely to provide more accurate assessments of patient adiposity, and results from
research employing alternate approaches are raising awareness that the use of BMI
and the BMI ≥ 30kg/m2 threshold to define obesity is underestimating rates of obesity
and the impact of obesity on patients [159, 160]. However, these types of data are not
standard clinical information and were not available for our analysis. Moreover, the data
used to calculate BMI (weight and height) are routinely available and the threshold BMI
≥ 30kg/m2 proved useful to establish that obesity is an adverse risk factor for TNBC [4,
5, 7-10].
2.5 Conclusions
The current report describes evidence to support that MBD2_v2 expression is
responsive to obesity and drives TNBC tumorigenicity, and thus provides molecular
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insights in support of the epidemiological evidence that obesity is a risk factor for TNBC.
The majority of TNBC patients are obese [161, 162] and rising obesity rates threaten to
further increase the burden of obesity-linked cancers [132], which reinforces the
relevance of this area of study.
These data also contribute to our understanding of CSC biology, and the function
of MBD2_v2 in driving tumor-initiating CSC self-renewal. More specifically, these data
provide evidence supporting that obesity could be driving the TNBC CSC subpopulation
via upregulation of MBD2_v2-mediated expression of transcription factors that regulate
pluripotency, such as NANOG, through aberrant activation of an evolutionarily
conserved epigenetic regulatory pathway. The mechanisms, by which MBD2_v2 is
directed to specific genomic regions, and directly or indirectly functions in positively
regulating gene transcription, have yet to be fully understood.
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Figure 1. Associations between expression of MBD2_v2 in TNBC patient tumor specimens and
survival outcomes and BMI. (A) Analysis was performed with the online KM Plotter database, using a
logrank test of association between relapse-free survival and MBD2_v2 transcript level. The number of
subjects at risk at different time points is indicated below the x-axis. Testing for gene transcript level
associations with BMI, was done using a separate gene expression microarray dataset generated from
TNBC specimens collected at the Karmanos Cancer Institute, Detroit, MI, where BMI data
corresponding to deidentified samples was available. (B) The association between BMI and MBD2_v2
expression was tested using linear regression analysis (P = 0.04, correlation 0.27). (C) The mean
MBD2_v2 expression for tumors from obese patients with BMI ≥ 30 was compared to the mean
MBD2_v2 expression for tumors from non-obese patients with BMI < 30. Line is equal to the median
value (BMI < 30 median = 2.7, BMI ≥ 30 median = 3.5). The P value was calculated using a Student’s ttest (one-sided). The number of patients (n) per group is indicated.
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Figure 2. Tumor formation frequency and tumor MBD2_v2 expression are increased in DIO mice.
(A) The mean body weight over time for DIO mice on the high-fat, calorie-dense formula diet and mice on
control formula diet. On day 35 the weight increase in DIO mice was 10%, P < 0.001. (B) MDA-MB-468 or
(C) MDA-MB-231 TNBC cells were used to inoculate control and DIO female mice by subcutaneous flank
injection. From time of inoculation, tumor formation frequency and time to initiation were measured over
150 days. The P values were calculated using Gray’s test. P values ≤ 0.05 are reported. (D) MDA-MB-468
and (E) MDA-MB-231 tumor mass was plotted for all tumors formed with modeled growth (bold)
superimposed. A generalized least squares test was used to calculate P values (P > 0.05). (F)
Semiquantitative RT-PCR analysis was performed to measure MBD2_v2 transcript levels in RNA harvested
from MDA-MB-468 tumors, comparing tumors harvested from DIO mice (n = 3 randomly selected) to those
from control mice (n = 3). Data are expressed as the relative means ± s.e.m., Welch’s t-test was used to
calculate the P value.
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Figure 3. MBD2_v2 overexpression in TNBC cells increases in vivo tumor initiation
capacity. (A) Stable overexpression of MBD2_v2 isoform in the MDA-MB-231 cell line was
confirmed by semiquantitative RT-PCR analysis (relative means ± s.d. of three technical
replicates); (B) and by immunoblot analysis of nuclear lysates, with nucleoporin p62 serving as the
loading control. (C) MBD2_v2 overexpressing MDA-MB-231 cells or GFP-expressing control
MDA-MB-231 cells were seeded equally under serum-free non-adherent conditions in a
mammosphere formation assay. Images documenting the differences in numbers of spheres
formed were taken after 7 days. Bar = 50 µm, 4x magnification. (D) MBD2_v2 overexpressing or
GFP-expressing MDA-MB-231 cells were subcutaneously inoculated by injection into the flank
regions of mice, n = 6 per group. At day 100, the difference in tumor formation frequency was
calculated (P = 0.02, Fisher’s exact test). At 150 days post inoculation, the difference in
cumulative incidence was also assessed (P = 0.12, Gray’s test).
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Figure 4. Knockdown of SRSF2 decreases MBD2_v2 levels in TNBC cells. (A) The effect of
(–)-epicatechin (Epi) antioxidant treatment (48 hours, 120 µM) to reduce readily detectable SRSF2
levels in MDA-MB-468 and SUM149 TNBC cell lines was measured by semiquantitative RT-PCR
analysis of RNA, (B) and by immunoblot analysis of protein lysates. Semiquantitative RT-PCR
(mean fold-change for sets of 3 technical replicates ± s.d.) and immunoblot data are
representative of 2 independent experiments for each cell line. (C) Confirmation of stable
knockdown of SRSF2 in MDA-MB-468 cells, and the impact of SRSF2 knockdown on MBD2_v2
levels, was measured by semiquantitative RT-PCR analysis (relative means of 3 technical
replicates ± s.d.); (D) and by immunoblot analysis. (E) A mammosphere formation assay was
used to simultaneously observe the impact of SRSF2 knockdown by each shRNA construct on
the numbers of mammospheres, (F) and the size of mammospheres formed. Images and counts
were taken 7 days after passaging to serum-free, non-adherent conditions. Results in E and F are
one complete set of data and are representative of 2 independent experiments. Bar = 500 µm, 4x
magnification. Welch’s t-test was applied to semiquantitative RT-PCR and mammosphere assay
data.
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Figure 5. Tumor SRSF2 expression is increased in DIO mice, and downregulation of SRSF2
hinders tumor formation. (A) Comparison of SRSF2 levels in wild-type MDA-MB-468 tumors
harvested from DIO mice (n = 3 randomly selected) and lean control mice (n = 3). Relative means
SEM, P value Welch’s t-test. (B) SRSF2 knockdown and nonsilencing vector control MDA-MB-468
cells were subcutaneously inoculated by injection into the flank regions of mice, n = 6 per group.
Gray’s test of diﬀerence in cumulative incidence was used to calculate the P value. (C) Analysis
was performed with the online KM Plotter database, using a logrank test of associations between
relapse-free survival and SRSF2 transcript levels. The number of subjects at risk at diﬀerent time
points is indicated below the x-axis.
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Figure 6. Summary and Conclusions. The mechanism underlying increased
TNBC risk associated with obesity remains unknown. Results of studying TNBC
cells in a diet-induced obesity mouse model and patient tumor data indicate
regulation of tumor-initiating cancer stem cells by mRNA variant MBD2_v2 is key.
Moreover, MBD2_v2 levels in TNBC cells, governed by ROS and splicing factor
SRSF2, increase under conditions of obesity.
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CHAPTER 3: MBD2_V2 PROMOTES SELF-RENEWAL CAPACITY OF PROSTATE
CANCER CSCS
The data presented in this chapter were published on June 12th, 2018 in the journal
Molecular Oncology [147].
3.1 Preface
RNA-sequencing of human tissue samples was performed in collaboration with
the KCI Genomics core, the Translational Genomics Research Institute (TGen), the
Wayne State University Department of Pathology and the KCI Biostatistics core
facility. Bioinformatic processing and quality control assessment were performed in
collaboration with Dr. Christophe Legendre at TGen. Statistical analyses were
performed in collaboration with Dr. Gregory Dyson at KCI.
3.2 Introduction
There are approximately 160,000 new cases of PCa and 26,730 PCa-related
deaths annually in the United States [125], making PCa the second leading cause of
cancer-related deaths for American men. Recent statistics also reveal that race
disparities persist despite improvements in PCa detection, access to care, and survival
across all demographics [117, 125, 126]. AAM have a 70% higher incidence rate and a
two-fold to five-fold greater risk of dying from the disease compared to EAM [117].
Moreover, AAM diagnosed with low-risk prostate cancer are more likely to harbor higher
risk disease [127]. The cause of these disparities is likely multifaceted, including
undetermined contributions from ancestry genetics and lifestyle risk factors [120-124],
(and reviewed in Powell and Bollig-Fischer (2013)). This raises the fundamental
motivation for our work: that the molecular underpinnings for race disparities in PCa,
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which remain to be understood, may one day be exploited to advance clinical decisionmaking and improve outcomes for all patients.
Traditionally, AAM have been poorly represented in reports of molecular genomic
aberrations in PCa. Recent research has begun to address this shortcoming and to
highlight the greater molecular complexity of the disease. Most notably, it is validated
that the tumor protein p53 (TP53) somatic aberrations and TMPRSS2-ERG fusions
occur significantly less often in tumors from AAM relative to EAM [163-167].
Amplification of the fatty acid synthase
(FASN) gene, however, was found to be more frequent in PCa samples from AAM
[163], and this is consistent with our finding that FASN mRNA expression is increased in
PCa from AAM relative to EAM [128].
In the current study, we performed RNA-sequencing analysis to further
understand the molecular diversity of PCa by specifically investigating high-grade PCa
[Gleason Score (GS) ≥ 7(4 + 3)] in relation to matched non-cancer adjacent tissue
across AAM and EAM. Here, our RNA-sequencing data analysis identified cytokine
signaling factors including IL-6 as showing race-specific differential expression. For
AAM, IL-6 was upregulated in the nonmalignant adjacent tissue, but for EAM, IL-6
expression was higher in PCa tissue.
Much effort has been put forth to study the mechanistic role of IL-6 in PCa,
supporting that IL-6 is a key cancer-promoting factor and rational therapeutic target
[168-170]. However, this narrative is challenged by reports such as one from Pencik et
al. (2015) showing that signal transducer and activator of transcription 3 (STAT3)
activation, the downstream effector of IL-6 signaling, suppresses PCa progression
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[171]. Moreover, clinical trials using antibodies to target IL-6 failed to provide benefit to
PCa patients [172, 173]. Yet, increased levels of IL-6 in patient serum associated with
poor outcomes [174], and serum IL-6 levels are known to be higher in AAM than in EAM
[175]. The importance of IL-6 in PCa race disparities remains unresolved.
In the US, AA patients have higher serum IL-6 levels, associated with higher
rates of obesity [46, 176, 177]. Moreover, obesity is associated with increased PCa risk
[113-116], and IL-6 signaling in PCa CSCs is linked with increased ROS, a hallmark of
obesity [169]. In Chapter 2, we demonstrated that obesity promoted tumor initiating
TNBC CSCs, via MBD2_v2 upregulation [57, 103]. We hypothesized that MBD2_v2
mediated regulation of CSCs could be similarly occurring, to drive PCa CSCs, as TNBC
also disproportionately impacts AAM, and both diseases are associated with obesityrelated risk.
The RNA-sequencing results that we report herein associated with AAM also led
us to recognize the potential for microenvironment-derived (exogenous) IL-6 to
inactivate tumor suppressor TP53 in PCa cells. The importance of TP53 downregulation
is in addition to the fact that TP53 somatic aberrations occur significantly less often in
tumors from AAM relative to EAM [163-167]. However, previous reports show that loss
of WT TP53 is required for CSC viability [178, 179], and that TP53 deletion and low p53
immunohistochemical positivity staining are both associated with worse PCa outcomes
[180]. As stated above AA PCa tumors harbor fewer TP53 mutations, suggesting that
TP53 inactivation could be epigenetically regulated.
Using a panel of PCa cells, including cell lines from AAM, we demonstrate that
exogenous IL-6 upregulates expression of MBD2_v2 to promote CSCs, and also

37
downregulates WT TP53 expression in IL-6 non-expressing PCa cell lines. The work we
describe here advances what is known about the biology associated with PCa race
disparities and molecular signaling promoting CSCs.
3.3 Results
3.3.1 RNA-sequencing analysis of PCa and non-cancer prostate tissue from AAM
and EAM
We analyzed RNA-sequencing normalized read count differences between tumor
and adjacent nonmalignant tissue samples as a function of race. Plots for the nine most
significant differentially expressed genes among the resulting 1206 significant coding
genes identified are provided in Fig. S3. We then applied the Enrichr tool [181] to the
significant gene set to identify significant signaling pathways overrepresented in the
data. Cytokine–cytokine receptor interaction was the most significant pathway (Fig. 1A).
The genes associated with this pathway in our dataset are provided in Table S2. Among
them, IL-6 and TGFB1 were upregulated in the non-cancer, tumor-adjacent tissue of
AAM, but for EAM, IL-6 expression was increased in PCa tissue and TGFB1 was not
differentially expressed (Fig. 1B). We further examined our significant gene set using
the Upstream Regulator tool [182]. Upstream Regulator analysis compared our input list
of differentially expressed genes to a catalogue of perturbed datasets to consider the
significance of gene overlap and direction of expression differences to predict the
activity of upstream regulators. This revealed a significant overrepresentation and
coordinated change in mRNA expression in AAM tumor data for genes that are known
to be regulated by tumor suppressor protein TP53 (Fig. 1C). Specifically, the direction of
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differential expression of genes downstream of TP53 suggested that TP53 inactivation
was occurring in PCa from AAM (Fig. 1D).
3.3.2 IL-6 treatment promotes CSC growth in IL-6 non-expressing PCa cell
cultures
Our RNA-sequencing analysis of high-grade PCa and non-cancer adjacent
tissues revealed differential IL-6 expression specific to race (Fig. 1). The data from AAM
suggest a paracrine role for IL-6, but IL-6 expression was enriched in PCa specimens
from EAM, indicating that for some high-grade tumors, PCa cells may express
autocrine-acting IL-6. We set out to further distinguish the role of IL-6 using a diverse
panel of PCa cells, including cell lines from AAM.
We began by characterizing IL-6 expression levels in our cell line panel. Based
on results of real-time RT–PCR analysis using TaqMan probes, IL-6 mRNA was not
detected in MDA-PCa-2b, RC77T or LNCaP cells, but was highly expressed in PC3 and
DU145 cells (Table 1). The results in Table 1 are annotated with the information that
MDA-PCa-2b and RC77T were derived from PCa from AAM. Also, the cell lines
expressing IL-6 are TP53 mutant. IL-6 mRNA was not detected in TP53 WT cell lines
(Table 1).
It was previously reported that IL-6 signaling in PCa sustains and promotes the
generation of CSCs [169, 183]. We proceeded to measure the impact that IL-6 had on
promoting CSCs across our PCa cell line panel. Using a prostasphere formation assay,
we tested whether IL-6 treatment influenced the formation of prostaspheres,
demonstrating the presence of CSCs [86]. In the AA-derived MDA-PCa-2b cells, which
do not express IL-6, we observed an increase in the number of prostaspheres after 7
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days of low-dose IL-6 treatment, with a higher IL-6 concentration eliciting a more
significant increase in the number of prostaspheres (Fig. 2A). We further observed that
within 48 h, MDA-PCa-2b cell viability also increased in a dose-dependent manner (Fig.
2B). We then tested IL-6 treatment on cultures of RC77T cells, which are also of AA
origin and TP53 WT, and do not express IL-6. Similar to MDAPCa-2b cells, IL-6
treatment induced greater numbers of prostaspheres (Fig. 2C) and increased cell
viability similar to MDA-PCa-2b cells (Fig. 2D). For PC3 cells, which are TP53 mutant
and express high levels of IL-6 endogenously, IL-6 treatment had no effect on
prostasphere growth (Fig. 2E). However, treatment of PC3 cells with the IL-6 receptor
inhibitor tocilizumab reduced prostasphere formation (Fig. 2F).
The impact of IL-6 on CSCs on other prostate cancer cell lines in our panel was
measured by fluorescence‐activated cell sorting (FACS), where the fraction of CSCs
was measured based on triple-marker-positive status (CD44+/CD133+/EpCAM+). This
assay distinguishes prominin 1 (CD133)-positive CSCs relative to non-CSCs, also
referred to as bulk cancer cells, which do not express CD133. CD133 is a specific PCa
CSC surface marker [91]. For IL-6 expressing DU145 cell line cultures, IL-6 treatment
for 7 days had no effect on the fraction of triple-marker-positive cell numbers. However,
for IL-6 non-expressing LNCaP cells, a similar 7-day IL-6 treatment regimen induced a
threefold increase in the percentage of triple- marker-positive CSCs (Fig. 2G, Table S3).
Results using PC3 again showed that IL-6 treatment had no effect on prostaspheres
(Fig. 2G). For IL-6 non-expressing RC77T cells, an increase in the percentage of triplemarker-positive CSCs was significant at 14 days of treatment (Fig. 2G, Table S3).
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3.3.3 IL-6 treatment induced expression of alternative mRNA splicing variant
MBD2_v2, which promotes CSCs
We

recently

identified

in

TNBC,

an

aggressive

BCa

subtype

that

disproportionately affects AA women [143], that expression of the epigenetic reader
protein and mRNA splicing variant MBD2_v2, is dependent on ROS and necessary to
maintain the CSC phenotype [57]. In generating PCa CSCs, IL-6 activity is coupled with
the production of ROS, which functions as second messenger signaling factor [169].
Therefore, we hypothesized that IL-6 treatment of PCa cells upregulates expression of
MBD2_v2 and that increased MBD2_v2 expression promotes PCa CSCs. We tested
this using IL-6 non-expressing RC77T and LNCaP cells. As can be seen from
immunoblot analysis, IL-6 treatment induced increased protein and mRNA expression of
the MBD2_v2 isoform in both cells lines (Fig. 3A,B). Levels of the long isoform, mRNA
variant MBD2_v1, were not affected by IL-6 treatment (Fig 3A). The addition of a
pharmacological STAT3 inhibitor blocked IL-6 induction of MBD2_v2 (Fig. 3C),
corroborating the role of exogenous IL-6 signaling via STAT3. Treatment with a STAT3
inhibitor alone downregulated MBD2_v2 (Fig. 3D), and prostaspheres (Fig. 3E) in IL-6
expressing DU145 cells, indicating that MBD2_v2 levels and prostaspheres were
sustained by the endogenous IL-6 signaling in this cell line. Regarding STAT3
immunoblotting, each of the panels (Fig. 3A,C,D) demonstrate that STAT3 phosphoprotein levels (pSTAT3) were induced by IL-6 treatment, while total protein levels were
unaffected, which is consistent with canonical IL-6 signaling.
We proceeded to stably overexpress MBD2_v2 in LNCaP cells to assess the
impact on CSCs via a prostasphere formation assay. Under nonattachment, serum-free
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conditions overexpression of MBD2_v2 led to a significant increase in prostasphere
numbers and an increase in prostasphere size relative to GFP expressing controls (Fig.
4A–C, Fig. S4). We subsequently performed the same experiment using the AA patientderived RC77T prostate cancer cell line, and the results were essentially the same (Fig.
4D–F, Fig. S4), underscoring that although a molecular phenotype may be enriched in
PCa from AAM (i.e., TP53 wild-type (WT), IL-6 derived from the environment), it is not
exclusive to PCa from AAM. A report by Lu et al. (2014) details the mechanism whereby
in hPSCs, MBD2_v2 activates genes such as NANOG and SOX2. It is well known that
SOX2 and NANOG directly interact and regulate self-renewal of hPSCs and CSCs [184186]. We proceeded to test whether MBD2_v2 regulates the mRNA expression of SOX2
and NANOG in the context of PCa cells. SRY-box 9 (SOX9) was also of interest to us
based on a recent report that it fulfills a molecular function similar to SOX2, but may
have a predominant role in therapy resistant PCa [187]. The results complete a set of
experiments providing evidence that exogenous IL-6 treatment upregulates MBD2_v2 in
TP53 WT LNCaP and RC77T cells (Fig. 3) and that upregulated MBD2_v2 by stable
overexpression in RC77T cancer cells upregulates NANOG, SOX2, and SOX9 (Fig.
4G–I). In LNCaP cells, only NANOG increased with MBD2_v2 overexpression (Fig. 4G).
Perhaps giving some indication of differences for these two cell lines that had up to now
in the course of our study appeared molecularly similar. Although based on the literature
the cell function outcome will be the same: increasing any single one of these factors
will likely promote the stemmness phenotype [184-187]
Finally, analysis of Affymetrix microarray expression data sets, accessed via
Oncomine [188], demonstrated that GS 8-9 PCa express significantly higher levels of
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MBD2_v2 relative to GS 4-7 PCa (Fig. 4J). Conversely, further analysis showed an
inverse relationship between variant MBD2_v1 expression and PCa GS (Fig. 4K).
3.3.4 IL-6 treatment decreased WT TP53 protein in IL-6 non-expressing cells
As described above, results of our RNA-sequencing data analysis pipeline
revealed that IL-6 was at significantly higher levels in the non-cancer, tumor-adjacent
tissue of AAM relative to PCa from AAM and tumor-adjacent tissue from EAM. Also,
although TP53 itself was not differentially expressed, the significant results from
Upstream Regulator Analysis identified evidence for inactivation of WT TP53 signaling
in PCa from AAM (Fig. 1C,D). We predicted that these findings were related and
hypothesized that microenvironment-derived IL-6, or exogenous IL-6 treatment in
culture, downregulates WT TP53 protein levels in PCa cells. WT TP53 function is
known to play a role in inhibiting the CSC phenotype [178, 179], thus, this hypothesis is
also relevant to IL-6 promotion of CSCs. To test it, we measured the effect of IL-6
treatment on TP53 levels using IL-6 non-expressing, TP53 WT cell lines RC77T and
LNCaP. Immunoblot analysis demonstrated that TP53 protein levels decreased in both
RC77T and LNCaP cells treated with IL-6 (Fig. 5A). Real-time RT–PCR analysis
validated that IL-6 treatment did not induce TP53 mRNA level changes (data not
shown). Also, for IL-6 expressing DU145 cells, IL-6 treatment had no effect on mutant
TP53 levels (Fig. 5A). Lastly, by real-time RT–PCR analysis we tested the effect of IL-6
treatment on the expression of genes that are known to be regulated by WT TP53
function using the RC77T cell line. We selected to test EPH receptor A2 (EPHA2) and
versican (VCAN) because they are among the significant results from the RNAsequencing data analysis results associated with specimens from AAM in Fig. 1D, and
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because they are regulated by direct TP53-DNA binding [189]. We also tested the more
commonly studied TP53-regulated factor cyclin-dependent kinase inhibitor 1A
(CDKN1A), otherwise known as p21. For all three genes, mRNA expression levels
decreased with IL-6 treatment (Fig. 5B).
3.4 Discussion
We began this investigation with RNA sequencing of PCa patient specimens,
which produced new evidence of molecular diversity for high-grade PCa associated with
race. Our analysis identified race-specific differential gene expression comparing tumor
and non-cancer adjacent tissue samples. Countering a previous report that PCa tumors
lack IL-6 expression [190], our RNA-sequencing data analysis highlighted that PCa
tumors from EAM, and by extension PCa cells, express relatively high levels of IL-6. We
measured IL-6 expression across a diverse PCa cell line panel. DU145 and PC3 PCa
cell lines expressed abundant IL-6 mRNA, but IL-6 was not detected in RNA harvested
from LNCaP cells. Okamoto et al. (1997) reported similar findings based on
measurement of IL-6 protein secreted from these cell lines [191]. Our panel also
included RC77T and MDAPCa-2b derived from AAM, and with this expanded panel, we
observed that IL-6 non-expressing PCa cell lines – LNCaP, RC77T, and MDA-PCa-2b –
are TP53 WT. In contrast, IL-6 expressing cell lines – DU145 and PC3 – are TP53
mutant. TP53 status in our diverse PCa cell line panel may reflect that TP53 mutations
are less frequent in PCa from AAM relative to PCa from EAM [163, 165].
The RNA-sequencing data analysis results associated with AAM led us to test
the potential for microenvironment-derived, or exogenous IL-6 to downregulate WT
TP53 protein in IL-6 non-expressing PCa cell lines. Immunoblot analysis showed that
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IL-6 treatment caused a marked decrease in TP53 protein levels in TP53 WT cell lines.
In parallel, we observed that IL-6 treatment had no effect on TP53 mRNA. Additional
studies are needed to uncover the mechanism by which, WT TP53 protein is
downregulated by IL-6 signaling in PCa cells. The requirement for TP53 downregulation
in PCa CSCs is underscored by its known role in promoting differentiation of ESCs, and
studies which show inactivation of TP53, supports reprogramming of somatic cells to
induced hPSCs [192]. However, it is already reported that loss of WT TP53 is required
for cancer cell expression of the stem cell phenotype [178, 179]. Moreover, low TP53
WT protein levels in PCa are associated with worse outcomes [180], but it remains
unclear whether higher IL-6 levels in the adjacent stroma and serum of AAM correlate
with low levels of WT TP53 protein in PCa specimens from AAM.
We characterized the effect of IL-6 on CSCs in our PCa cell line panel.
Summarizing the results of these experiments, IL-6 treatment of IL-6 non-expressing
PCa cells elicited a significant, dose-dependent increase in the number of CSCs. For IL6- expressing PCa cell lines, adding IL-6 to the media of IL-6-expressing cells did not
increase the number of CSCs. These data suggest that in IL-6-expressing PCa cell line
cultures the IL-6 receptor population was saturated by endogenous IL-6 levels. Our
work underscores that previous, unsuccessful clinical trials appropriately assessed the
significance of IL-6 signaling in PCa progression, but may have failed in their approach
to target IL-6 or IL-6 signal transduction factors JAK/STAT [172, 173, 193, 194]. Zhong
et al. (2016) propose that a higher affinity IL-6 antibody with an extended half-life will
contribute to solving the issue [170]. On the other hand, more thorough understanding
of downstream IL-6 signaling mechanisms driving PCa CSCs could provide insights for
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improved PCa treatment strategies. Our finding that IL-6 signaling upregulates
expression of MBD2_v2, to support and promote expansion of the CSC niche in PCa,
opens a novel avenue for research. CSCs are identified in patient tumors and tumorderived cell line cultures as a subfraction of self-renewing, tumor-initiating PCa cells that
also give rise to drug resistance and metastatic recurrence [79]. The insight for us to
test the effect of exogenous IL-6 treatment on MBD2_v2 expression, and subsequently
observe that upregulated MBD2_v2 increases PCa CSCs, is based on results of our
investigation into how ROS signaling promotes malignant transformation and the stem
cell phenotype in TNBC cells [57]. Our current study identified that MBD2_v2 sustains
PCa CSCs. Furthermore, a pro-inflammatory signaling environment (i.e., exogenous IL6) induces MBD2_v2 expression that drives expansion of the CSC population in TP53
WT PCa cells, in a STAT3-dependent manner. With these two studies, we have
uncovered a mechanism implicated in two cancer types that disproportionately impact
African Americans.
We intend to pursue studies to uncover further mechanistic insights surrounding
how MBD2_v2 expression is regulated by IL-6 in PCa. However, we can hypothesize
that the mechanism by which MBD2_v2 functions to maintain and promote the
generation of CSCs is similar to the mechanism described for hPSCs. MBD2_v2 is one
of two alternative mRNA splicing variants for the epigenetic reader MBD2 gene and in
hPSCs MBD2_v1 binds methylated CpG promoter sequence and recruits the NURD
corepressor complex to silence transcription of pluripotency genes and promote cellular
differentiation [112]. MBD2_v2 binds the same promoter sequences, but lacks the
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domain required to recruit the NuRD complex; and upregulated MBD2_v2 displaces
MBD2_v1 to promote stem cell phenotypes [112].
Analysis using the Oncomine gene expression microarray database [188]
showed that high MBD2_v2 expression in patient tumors correlated with high-grade
PCa and that high MBD2_v1 expression correlated with low-grade PCa. We do not yet
have preliminary insight as to whether MBD2_v2 is differentially expressed in PCa from
AAM relative to EAM. Public gene expression data sets are lacking in AAM specimens,
and despite having achieved approximately 100 million high-quality paired end reads
per sample, MBD2_v2 mapped read counts were below the detection threshold in our
RNA-sequencing data. This underscores the challenge of using genomewide RNA
sequencing to analyze specific mRNA splicing variants [195].
Based on data from previous studies with a focus on PCa tissue, there appears
to be no association between IL-6 levels in cancer cells and high-grade PCa [128, 171].
Herein, we report that AAM with high-grade cancer have significantly higher IL-6
expression in the tumor microenvironment. Furthermore, AAM have higher circulating
levels of IL-6 relative to EAM [127], and AAM are more likely to advance to higher grade
disease [127]. Thus, further research to define the signaling mechanism for induction of
MBD2_v2 expression in PCa, by IL-6 derived from the microenvironment, may be
particularly relevant for AAM.
3.5 Conclusions
In conclusion, the results of the current study contribute to characterizing gene
expression patterns in high-grade PCa and non-cancer tissues from EAM and AAM.
The results advance molecular understanding of how IL-6 signaling promotes the CSC
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phenotype in PCa cells derived from EAM and AAM (Fig 6.). Continued research is
warranted to realize how these new insights for CSC biology can be exploited to
overcome PCa race disparities and improve outcomes for all men.
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Figure 1. Analysis of RNA-sequencing data from PCa and matched noncancer adjacent tissue
identified race-specific differential gene expression. RNA sequencing and interaction effect
analysis were run on PCa and matched noncancer adjacent tissues from eight AAM and eight EAM
(32 samples total, repeated). (A) The Enrichr tool was applied to the resulting significant gene set to
identify KEGG signaling pathways overrepresented in the data. (B) Race-specific, differential gene
expression patterns are shown for TGFB1 and IL-6, which were among the genes contributing to
significant overrepresentation of the cytokine–cytokine receptor interaction pathway in (A). The
interaction effect analysis P-value is provided. (C) Upstream Regulator analysis compared our input
list of differentially expressed genes to a catalogue of perturbed datasets to consider the significance
of gene overlap and direction of expression differences to predict the activity of upstream regulators,
for example, transcription factors. The algorithm accounts for the direction of differential expression of
genes downstream of an upstream regulator to calculate a negative activation z-score (predictive of
inactivation) or a positive activation z-score (predictive of activation). (D) Enriched network of genes
associated with TP53 function identified by Upstream Regulator Analysis. The patterns of expression
displayed here represent PCa relative to noncancer adjacent tissues specific to AAM. Green nodes
showed significant (P ≤ 0.05) decreased expression, and red nodes were significantly increased. The
edges connecting TP53 to other genes represent published regulatory relationships: blue activating
expression and orange inhibitory. The result indicates that although TP53 mRNA levels were not
different for either EAM or AAM, TP53 function was being inactivated in PCa from AAM.
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Figure 2. IL-6 treatment induced prostasphere formation in IL-6 nonexpressing PCa cell
line cultures. (A) Effect of IL-6 treatment relative to vehicle control on the numbers of
prostaspheres in 7-day cultures of MDA-PCa-2b cells. (B) Effect of IL-6 treatment (72-h) on
viability of MDA-PCa-2b cells, run in triplicate and repeated twice. (C) Effect of IL-6 treatment
relative to vehicle control on the numbers of prostaspheres in 7-day cultures of RC77T cells. (D)
Effect of IL-6 on viability of RC77T cells, 7-day treatment run in triplicate and repeated twice. (E)
Effect of 7-day IL-6 treatment on the numbers of PC3 prostaspheres. (F) Effect of IL-6 receptor
inhibitor tocilizumab (10 lM, 7 days) on prostaspheres in PC3 cultures. (G) Impact of IL-6
treatment on the percentage of CSCs in other cell lines in our panel measured by FACS analysis.
Cells were treated with IL-6 at 10 ngmL1 for 7 or 14 days for RC77T. The fraction of CSCs
relative to total cell count was measured based on CSC triple-marker-positive status (CD44+/
CD133+/EpCAM+). The results are presented as fold-change, IL-6 treated vs. control.
Prostasphere assay and FACS data are representative of repeated experiments and are the
average of three independent biological replicates. *P ≤ 0.05, **P ≤ 0.01.
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Figure 3. Activation of IL-6 signaling upregulated expression of the MBD2 short isoform
MBD2_v2 in PCa cell lines. (A) Immmunoblot analysis of MBD2 isoforms, phosphorylated STAT3
(pSTAT3), and total STAT3 protein levels in IL-6 nonexpressing cell lines LNCaP and RC77T
treated with IL-6 (10 ngmL1, 14 days) or diluent control. (B) MBD2_v2 mRNA levels in LnCaP and
RC77T cell lines measured by real-time RT–PCR using TaqMan probes. Results are presented as
fold-change, IL-6-treated relative to vehicle-treated conditions. (C) Immunoblot analysis of MBD2
isoforms, pSTAT3, and total STAT3 protein in LNCaP cells treated with IL-6 in combination with the
STAT3 inhibitor drug cryptotanshinone (CTS, 500 nM) or vehicle control for 14 days. (D)
Immunoblot analysis of MBD2 isoforms, pSTAT3, and total STAT3 protein in IL-6-expressing cell
line DU-145, treated with CTS (500 nM) or vehicle control for 48 h. Cell culture treatment, protein
harvest, and immunoblot analysis were carried out three times. (E) Effect of CTS treatment relative
to vehicle control on the numbers of prostaspheres in 7-day cultures of DU145 cells. **P ≤ 0.01.
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Figure 5. IL-6 treatment downregulated wild-type TP53 protein levels in non-IL-6
expressing PCa cell lines. (A) TP53 immunoblot analysis of IL-6 nonexpressing, TP53
wild-type RC77T, and LNCaP cell lines, and TP53 mutant DU-145 cells, each treated with
IL-6 or vehicle control for 7 days. (B) RT-PCR analysis of IL-6 nonexpressing, TP53 wildtype RC77T, and LNCaP cell lines treated with IL-6 or vehicle control for 7 days. (C) RT–
PCR analysis of mRNA expression levels of known TP53-regulated genes in RC77T cells
treated with IL-6 or vehicle control for 7 days. Cell culture treatment, protein harvest, and
immunoblot analyses were carried out three times.
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Figure 6. Summary of Conclusions. RNA-sequencing analysis of patient specimens
and a systematic investigation of the role of exogenous and endogenous IL6 across a
diverse prostate cancer cell line panel brings new understanding of IL6 expression
patterns and signaling that drive prostate cancer stem cell-like cells, and underscores
the potential importance of IL6 in PCa race disparities.
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CHAPTER 4: SUMMARY AND CONCLUSIONS
4.1 Overview
Obesity is an important risk factor for both TNBC and PCa. Others and we have
shown that pro-inflammatory features associated with obesity, including upregulated
production of ROS as well as leptin and insulin signaling, promotes CSCs and
expression of pluripotency transcription factors [49-57]. What drives pluripotency
transcription factor expression in these CSCs, downstream of these obesity-associated
signaling pathways is still elusive. In our most recently published study from the BolligFischer lab, we discovered that we could inhibit TNBC CSCs by neutralizing ROS, a
feature of obesity, in culture by treatment with hydrogen peroxide targeted antioxidants.
For insights as to what genes might be impacted by antioxidant treatment, and
regulating the CSC phenotype, we used a microarray approach to measure wholegenome expression in antioxidant treated TNBC cell cultures. There we discovered that
antioxidant treatment resulted in the downregulation of MBD2. Further we found that
specific downregulation of the mRNA splicing variant MBD2_v2, was important for CSC
self-renewal in vitro, and demonstrated that overexpression of MBD2_v2 promoted selfrenewal capacity of TNBC CSCs in culture, and was highly expressed in CSC versus
bulk cancer cells [57].
Given that obesity is coupled with increased ROS, we hypothesized that obesity
might fuel this mechanism to drive CSCs via MBD2_v2 expression. The work presented
in this thesis addressed that hypothesis, associating MBD2_v2 expression with obesity
in TNBC patients, and highlighting the importance of MBD2_v2 expression in promoting
both TNBC and PCa CSCs. For example, we discovered that high MBD2_v2 tumor
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gene expression is associated with worse outcomes and obesity in TNBC patients, and
is relevant in high-grade PCa tumors. Moreover, we find a link between MBD2_v2
expression and expansion of tumor-initiating CSCs with obesity in mice, and
demonstrate that MBD2_v2, in addition to being ROS-sensitive, is also upregulated by
the obesity-associated pro-inflammatory cytokine IL-6, which promotes PCa CSCs in a
STAT3-dependent manner.

Finally, we show that similar to hPSCs [112], SRSF2-

mediated MBD2_v2 upregulation drives expression of pluripotency transcription factors,
including NANOG (Fig. 1).
Altogether these findings provide significant advancements in understanding of
obesity-associated pro-inflammatory signaling and ROS, in driving TNBC and PCa
CSCs through MBD2_v2. MBD2_v2 upregulation could likely be downstream of many of
the already identified obesity-associated signaling pathways, which promote CSCs [4957]. Our studies indicate that MBD2_v2 upregulation is relevant in tumor initiating TNBC
CSCs, linked to obesity, suggesting that targeting of MBD2_v2 could be clinically
important in all TNBC, and more so in obese TNBC patients. Moreover, as we identified
that MBD2_v2 regulates self-renewing CSCs and is specifically expressed in TNBC
CSCs, our data suggest that MBD2_v2 could be useful as a functional CSC biomarker
for research. Lastly, we find that similar to hPSCs [112], which require MBD2_v2
regulated NANOG expression for pluripotency, MBD2_v2 also supports NANOG
expression in CSCs; which is promoted by ROS-dependent expression of the SRSF2
splicing factor. However the way in which ROS activates SRFS2, and how MBD2_v2
regulates positive transcriptional regulation, needs to be further studied, in order to
better understand the mechanistic function of MBD2_v2 versus MBD2_v1.
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4.2 Clinical Implications
Within a primary tumor, the CSC niche both self-renews and asymmetrically
divides, leading to growth of a heterogeneous population of cancer cells, and thus
CSCs are intrinsically tumor forming. CSCs are also highly quiescent, providing inherent
resistance to cytotoxic treatments, which target rapidly dividing tumors cells, associated
with primary tumor reoccurrence [78]. However, dissemination of primary tumor cells to
distant sites, through a process called metastasis, is the primary complication
associated with cancer-related death; and studies show that as few as 0.1% of
disseminated tumor cells may actually seed and subsequently have the ability to form
macrometastases in a non-native tissue or organ [84]. CSCs, which are enriched in
obese patients [49-57], are also associated with clinical cancer metastasis and support
metastatic growth of tumors [58-71]. Therefore targeting CSCs could improve patient
outcomes by preventing further metastatic growth of tumor cells and reoccurrence.
Based on the data collected in this study, we’ve uncovered several ways to
potentially target CSCs. In our studies we demonstrate that treatment with chemicallyderived antioxidants, such as (-) epicatechin, as well as engineered catalase biologics
[57], can inhibit CSC growth by downregulating expression of SRSF2-MBD2_v2. In
addition, we have demonstrated that the potent STAT3 inhibitor, cryptotanshinone
(CTS), downregulates MBD2_v2 expression in PCa cell lines and also inhibits CSC
growth. Finally, we realized the potential for IL-6 receptor inhibition, as the humanized
anti-IL-6 antibody based biologic Tocilizumab, inhibited PCa CSC growth. Our preclinical studies however were all performed in vitro. Testing the impact of STAT3
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inhibitor, Tocilizumab, or antioxidant treatment on tumor forming CSCs in vivo, will be
crucial for assessing the utility of these treatment approaches in patients.
4.3 MBD2_v2 as an Functional CSC Biomarker
Cell surface markers, such as human CD44 molecule (CD44), CD133, and
epithelial cell adhesion molecule (EpCAM), have been used to identify CSCs in BCa
and PCa; in addition to the intracellular antigen aldehyde dehydrogenase 1 family
member A1 (ALDH1). However these well-established CSC markers have yielded
conflicting results, in that they do not correlate well with one another, and only a small
percentage of some marker positive cell populations have been shown to be tumor
forming. [196, 197]. Significant overlap between identification of normal adult stem cells
and CSCs is also an issue, such as CD133 in PCa [64, 198-204]. Moreover, the
antibody-based techniques, which are used to identify CSCs in research and patient
tumors, have a lot of issues with reproducibility [78]; which is underscored by even
current reproducibility concerns with measurement of clinical BCa biomarkers by
immunohistochemical staining [205]. In order to more accurately identify CSCs in
research and in clinical patient specimens, there is still a great need for a CSC-specific
biomarker, which can be detected by highly sensitive and more precise technologies.
We find that MBD2_v2 expression is higher in CSC versus bulk cells in TNBC cultures
[57], suggesting that MBD2_v2 could be a good candidate for development of a CSCspecific functional biomarker.
Unlike other CSC markers, identification of MBD2_v2 would likely be performed
by gene expression versus antibody-based assays, given its significant homology with
other MBD family members, and nuclear localization [104]. Between MBD2 transcript
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variants, there is only a short c-terminal end differentiating these two mRNA species,
and MBD2 and MBD3 share significant homologies [104, 206]. However, in our studies
we were able to use qRT-PCR, to very specifically measure MBD2_v2, using a Taqman
Assay with exon spanning probes (Thermo Fisher Scientific, Assay ID: Hs00210557).
This primer/probe based approach provides both specificity and reproducibility needed
for research purposes as well as clinical testing, using as little as 1 ng RNA input.
In addition to a Taqman assay-based approach, we were able to associate
MBD2_v2 expression in patient tumors with BMI, RFS, and GS from microarray
datasets, which utilize splice variant specific probes. Unfortunately, we were not able to
measure MBD2_v2 in PCa samples using RNA-seq, and this may be due to challenges
associated with using RNA-seq to analyze specific mRNA splicing variants, which have
been reported [195]. Although we were able to consistently detect and measure
MBD2_v2 in patient samples, using microarray based technology, and in TNBC cell
line-derived tumors and cultures with semi-quantitative RT-PCR, more research is
needed to assess MBD2_v2 CSC-specificity in both TNBC and PCa. Encouragingly,
the specific expression of MBD2_v2 we identified in TNBC CSCs, could be paramount
in its potential as a CSC-specific biomarker.
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Figure 1. Summary and Conclusions. MBD2_v2 pathway extrapolated from mechanistic evidence in
TNBC cell lines and tumors, as well as in PCa cell lines related to IL-6 signaling. Potential approaches for
therapeutic targeting of CSCs, are denoted by red inhibitor interactions.
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CHAPTER 5: MATERIALS AND METHODS
5.1 BCa cell lines and culture conditions. TNBC cell lines MDA-MB-468 and MDAMB-231 were acquired from the Biobanking and Correlative Sciences Core at KCI
where they were passaged and authenticated by short tandem repeat (STR) analysis
using the PowerPlex(r) 16 system (Promega, Madison, WI) immediately prior to use
in this study. MDA-MB-468 and MDA-MB-231 cells were then cultured in 10% FBS
DMEM media, at 37 °C, 5% CO2. SUM149 cells, developed by and acquired from Dr.
Stephen Ethier [207], were cultured in 5% FBS HAM F-12 media containing 1 µg/ml
hydrocortisone and 5 µg/mL human insulin, and authenticated by STR analysis using
the PowerPlex(r) 16 System from Promega (Madison, WI).
5.2 Immunoblot analysis. Immunoblot analysis was performed as we have done
previously [57]. Briefly, protein lysates were harvested using NE-PER Nuclear and
Cytoplasmic Extraction Kit (Thermo Fisher Scientific, Waltham, MA, cat#78833) and
concentrations measured by the Bradford assay. Protein samples (50 µg) were
separated on a 10-12% SDS-PAGE gel in a Noxex XCell SureLock™ Mini-Cell
Electrophoresis

System

(Invitrogen™,

Waltham,

MA)

and

transferred

to

a

nitrocellulose membrane (GE Healthcare, Pittsburgh, PA) using Mini Trans-Blot
Electrophoretic Transfer Cell (Bio-Rad, Hercules, CA). Membranes were probed with
primary antibodies following supplier recommendation and secondary peroxidaseconjugated antibodies (anti-mouse or rabbit) from Vector Laboratories (Burlingame,
CA). Primary antibodies targeting human MBD2 (Bethyl Laboratories, Montgomery,
TX,

cat#A301-633A-M),

SRSF2

(Abcam,

Cambridge,

United

Kingdom,

cat#ab204916), TP53 (Thermo Fisher Scientific, Waltham, MA, cat#MS105P0);
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STAT3 and pSTAT3 (Abcam, Cambridge, UK, cat#ab119352 and ab76315); and
nucleoporin p62 (BD Biosciences, Franklin Lakes, NJ cat#610497).
5.3 Semi-quantitative RT-PCR analysis. Real-time RT-PCR analysis was performed
as previously by our lab [57, 208]. RNA was harvested from pulverized snap frozen
tumors surgically excised from euthanized mice, or from cultured cell lines using the
RNeasy mini kit from Qiagen (Valencia, CA). RNA samples derived from snap frozen
tumors were further purified using the OneStep PCR Inhibitor Removal kit (Zymo
Research, Irving, CA, cat#D6030), prior to RT-PCR. The High-Capacity RNA-to-cDNA
Kit (Thermo Fisher Scientific, cat#4387406) was used to prepare cDNA. MBD2_v2,
IL-6 and the ribosomal protein lateral stalk subunit P0 (RPLPO) TNBC reference or
beta actin (β-Actin) PCa reference control genes were measured using TaqMan
assay reagents (Fisher Scientific, cat#Hs00210557, Hs00985639, Hs99999902 and
Hs99999903). PCR primers synthesized by IDT (Coralville, IA) and FastStart SYBR
Green Master Mix (Roche, Indianapolis, IN) were used to analyze SRSF2, NANOG,
CDKN1A, VCAN, EPHA2, SOX2, SOX9, (PrimerBank IDs [209]: 306482644c1,
153945815c3, 310832423c2, 255918075c1, 296010835c1, 325651854c2, and
182765453c1) and the β-Actin control gene (forward:CCCAGCACAATGAAGATCAA,
reverse: ACATCTGCTGGAAGGTGGAC). For these experiments, 20 uL reactions
were run in 96-well plates using 100-1000ng cDNA. Reactions were run in triplicate
using the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City,
CA). Relative expression was calculated by the ΔΔct method [210].
5.4 Mammosphere and Prostasphere formation assays. The presence and selfrenewal capacity of CSCs was examined in TNBC and PCa cell cultures by sphere-
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propagating assays, as described previously [57, 86]. Briefly, 1000 single cells were
seeded in 1.5 mL of the FBS‐free sphere formation media (1:1 DMEM: F-12 media plus
with B-27 and N-2 supplements, Gibco Brand, ThermoFisher, Waltham, MA, USA) in
six-well Ultra Low Attachment plates (Corning Inc., Corning, NY, USA). Treatments
were added and media replenished every 3 days. After 7 days of incubation, the
mammospheres or prostaspheres (at a size equal or greater than 50 µm diameter) were
counted and reported as a fraction of the total number of cells seeded. Images were
taken using a Nikon Eclipse TE2000-U microscope (Tokyo, Japan).
5.5 Animal work. All experiments using mice received prior approval from the WSU
Institutional Animal Care and Use Committee. Sample size was arrived at empirically
and was not predetermined by statistical methods. Female 5-week old B6.Rag1 -/mice were purchased from Jackson Laboratory (Bar Harbor, ME, cat#002216) and
were acclimated for 1 week on standard chow diet. After 1 week, all mice were
switched to and thereafter maintained on a purified diet. For experiments assessing
tumor formation without consideration of DIO, mice were fed a control formula (kcal
fat%=10, gram%=4.3) from Research Diets (New Brunswick, NJ, cat# D12450B). To
study the effects of DIO, groups of mice were randomized to receive the control
formula diet or a high-fat matched formula (kcal fat%=60, gram%=35, Research
Diets, cat# D12492). At 11 weeks old, mice were aseptically inoculated with cancer
cells, in the flank, subcutaneously by injection using a 1cc TB syringe with a 25g ½-inch
needle, in a volume of 0.1-0.25 mL with matrigel (1:1 ratio). Resulting tumor mass (mg)
was calculated based on caliper measurements (Tumor Mass = (lw2)/2). For
assessing cell line tumor formation frequency mice were bilaterally inoculated
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subcutaneously in the flank region (MDA-MB-231 left and MDA-MB-468 right) at 105,
106 and 107 cell titers, 6 inoculations per cell line titer, with a total of 36 inoculations
in 18 mice. In experiments assessing effects of DIO on tumor formation, mice were
inoculated with MDA-MB-231 cells at 105, 106, and 107 cell titers (bilaterally), and with
106 MDA-MB-468 cells (unilaterally). For these experiments there were 6 inoculations
for MDA-MB-231 control groups (3 mice) for each titer and 8 inoculations in MDA-MB231 DIO groups (4 mice) for each titer (21 mice total). For the MDA-MB-468 cell line
there were 6 inoculations per diet group (12 mice total). To compare MBD2_v2
overexpressing and GFP-expressing MDA-MB-231 cell lines, mice were unilaterally
inoculated with 105 cells, using 6 mice per cell line (12 total mice). To compare tumor
formation by SRSF2 KD and non-silencing shRNA control MDA-MB-468 cells, DIO
mice were unilaterally inoculated with 105 or 106 titers, using 6 mice per cell line per
titer (24 mice total).
5.6 Testing for associations between MBD2_v2 expression levels and patient
outcomes and BMI. Association analysis was performed using the Kaplan-Meier
Plotter database for BCa [211]. Associations between RFS and gene expression were
determined for MBD2_v2 and SRSF2. Analysis was restricted to ERα-, PR- and
HER2-negative tumors, i.e., TNBC. For MBD2_v2, the transcript-specific probe
214396_s_at was used to query data combined from 5 datasets: E-MTAB-365,
GSE19615, GSE21653, GSE2603, GSE31519. Auto select best cutoff and Censor at
threshold options were selected. Quality control included removal of redundant samples
and exclusion of outlier arrays. The same parameters and combined data sets were
used in analysis of SRSF2 expression using the probe 200753_x_at, identified as being
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optimal by the JetSet best probe function [212]. Microarray gene expression data from a
retrospective cohort of archived formalin fixed paraffin embedded tumors from African
American women diagnosed with TNBC at the Karmanos Cancer Institute between
2004-2010 were used to analyze the relationship between gene expression and BMI.
Gene expression data were generated using the GeneChip™ Human Gene 2.1 ST
Array after amplification of RNA using the Affymetrix WT Pico Kit (Affymetrix, Santa
Clara, CA). Raw probe intensity data were normalized as implemented by the “rma”
function in R to perform background subtraction, quantile normalization, and log 2
transformation. Probe sets were not summarized to allow analysis of alternative
splice variants of our genes of interest. Linear regression analysis was performed,
followed by a t-test (one-sided) to measure significance of the mean increase for
MBD2_v2 expression in tumors from patients with BMI ≥ 30 (n=28) relative to BMI <
30 (n=31). Methods conformed to the standards set by the Declaration of Helsinki and
were reviewed by the Wayne State University Institutional Review Board.
5.7 Genome-wide expression profiling of tumors harvested from mice. RNA was
isolated from MDA-MB-468 cell line-derived tumors harvested from lean control mice
(n=3) and DIO mice (n=3). Genome-wide expression was measured using the SurePrint
G3 Human Gene Expression 8x60K Microarray and Low Input Quick Amp Labeling kits
(Agilent Technologies, Santa Clara, CA). Arrays were scanned on the SureScan
Microarray Scanner System. Data extraction was performed using Agilent Feature
Extraction software. The "limma" package in R was used to perform normal-exponential
convolution (with an offset of 50) background correction; loess normalization within
arrays; and quantile normalization across arrays. The difference in gene expression (per
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gene) was assessed by adjusting for multiple probes per gene, unequal variance within
groups and correlated observations within the generalized least squares model
framework. The resulting set of significant (P ≤ 0.05) differentially expressed genes
(RefSeq coding IDs) were analyzed for further significance according to gene
ontological (GO) enrichment analysis using DAVID [213] and ChEA 2016 using
ENRICHR [181, 214]. The data set is available through Gene Expression Omnibus
accession number GSE114604.
5.8 RNA sequencing of patient samples. Specimen collection and analysis were
carried out with the understanding and written consent of each subject. The study
methodologies conformed to the standards set by the Declaration of Helsinki and were
approved by the Wayne State University Institutional Review Board. RNA sequencing
was applied to matched PCa and adjacent non-cancer prostate tissue specimens from
16 patients, eight AAM and eight EAM, for a total of 32 samples. All PCa specimens
represented an aggressive phenotype, with GS ≥ 7(4 + 3) [215]. De‐identified, FFPE
high‐grade PCa (greater than 70% cancer cell content) and matched adjacent
nonmalignant tissue samples were identified and reviewed at the Biorepository in the
Department of Pathology at Wayne State University, Detroit, MI. Total RNA was isolated
from the FFPE specimens (eight sections, 10 µm each per block; discarding surface
section) using the Recover All kit for FFPE, with extended proteinase K and DNAse
treatment (Life Technologies Inc., Carlsbad, CA, USA). RNA quantity and quality were
estimated by spectrophotometry. Double‐stranded cDNA preparation and library
construction were done with the Ovation Human FFPE RNA‐Sequencing Multiplex
System (NuGEN, San Carlos, CA, USA) using 200 ng total RNA. Key features are as
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follows: it is strand‐specific; no poly‐A selection step (or other selection step that could
introduce bias or be problematic for degraded RNA); and the approach integrates an
insert dependent adapter cleavage step that specifically targets ribosomal RNA for
degradation [216]. Quality of library preparations was assessed using the Tapestation
(Agilent, Santa Clara, CA, USA). Cluster generation was performed using the Illumina
cBot and HiSeq Paired End Cluster Generation Kit (Illumina, San Diego, CA, USA).
Flow cells were paired end sequenced (100 cycles) on an Illumina HiSeq 2500 (high‐
output mode). Sample libraries were indexed and multiplexed in randomized fashion:
four

per

lane

of

an

8‐lane

flow

cell.

FastQC

analysis

(www.bioinformatics.babraham.ac.uk/) was done to know that more than 85% of reads,
for all samples, passed QC30. Transcript and gene‐level expression abundances were
calculated using the cufflinks2 module from the Cufflinks2 Suite [217, 218]. The
abundance results were reported in plain text files showing P‐values (adjusted for
multiple testing) and normalized abundance data in terms of FPKM (fragments per
kilobase of transcript per million mapped reads).
In an additional quality control step, we ran a test of the nonparametric
Spearman correlation between identical samples sequenced twice, in different batches,
which demonstrated high reproducibility (98%, data not shown). We also compared our
RNA‐sequencing data with expression data from our published study that employed
microarray‐based analysis [128]. Applying nonparametric Spearman correlation analysis
to measurements from the two technologies yielded a high correlation (0.805 AAM and
0.811 EAM), signifying that the results of high‐throughput sequencing compared to gene
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expression measured by validated microarray analysis across the bulk of genes
analyzed by both methods, even though the PCa samples studied were different.
5.9 Statistical analysis of RNA sequencing data. Matched high‐grade [GS ≥ 7(4 + 3)]
prostate tumor and adjacent normal specimens from 16 patients (eight AAM and eight
EAM) were subjected to two replicate runs of RNA‐sequencing analyses. The standard
FPKM per transcript were normalized by adding 1 and applying a log‐transformation. A
mixed model analysis was used to model normalized read count as a function of race,
tissue type (tumor or normal), and their interaction for each transcript, accounting for the
correlation between replicates and different variance in the two batches. The outcomes
identified transcripts with a significant (P ≤ 0.05) interaction effect between race and
tissue type. FASTQ and processed data are available at Gene Expression Omnibus
GSE104131. The Enrichr tool [181] was applied to the resulting significant gene list to
identify significantly overrepresented KEGG pathways (P ≤ 0.05). The Upstream
Regulator analysis tool [182] included in the Ingenuity Systems (Qiagen, Redwood City,
CA, USA) software suite, was used to identify significant overenrichment (P ≤ 0.05) for
subsets of genes associated with activation or inactivation of upstream regulators.
5.10 PCa cell lines and culture conditions. The established PCa cell line MDAPCa-2b was newly purchased from ATCC

(Manassas, VA) for this study. The

established cell lines LNCaP, PC3 and DU-145 were acquired from the Biobanking
and Correlative Sciences Core at KCI where they were passaged and authenticated
by STR analysis using the PowerPlex(r) 16 system (Promega, Madison, WI)
immediately prior to use in this study. RC77T PCa cell line was established and
provided to us by Dr. Clayton Yates [219]. LNCaP, PC3 and DU-145 cells were
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maintained in 10% FBS RPMI-1640 media containing 50 µg /mL gentamycin at 37 °C,
5% CO2. RC77T cells were seeded on plates coated with FNC Coating Mix™
(ATHENA, Baltimore, MD, cat#0407) in Gibco keratinocyte-SFM media (Thermo
Fisher, Waltham, MA, cat#10724-011), supplemented with EGF and BPE, with 2%
FBS immediately added to each plate after splitting. FBS containing media was
replaced by keratinocyte-SFM media, supplemented with EGF and BPE, 24 hrs after
splitting or seeding and RC77T cells were maintained at 37 °C, 5% CO2. MDA-PCa2B cells were maintained in 10% FBS F-12K media (Corning Inc., Corning, NY,
cat#10-025-cv,) containing 1% penicillin/streptomycin supplemented with 25 ng/mL
cholera toxin, 10 ng/mL EGF, 0.005 mM phospho-ethanolamine, 100 pg/mL
hydrocortisone, 45 nm selenious acid at 37 °C, 5% CO2.
5.11 PCa cell line treatments. IL-6 was purchased from BD Biosciences (Franklin
Lakes, NJ). STAT3 inhibitor CTS was purchased from Sigma-Aldrich (St. Louis, MO,
cat# C5624-5MG). The IL-6 receptor inhibitor drug, Tocilizumab (Genentech, South
San Francisco, CA), was from the Karmanos Cancer Institute pharmacy. See results
and figures for all concentrations and treatment times used in each experiment.
5.12 Viability Assays. For viability assay, cells were seeded at 3000 cells/well in 96well plates, and incubated at 37 °C, 5% CO2 for 24 hrs. Cells were then treated with 0.5
ng/mL, 10 ng/mL or no IL-6 from BD Biosciences (Franklin Lakes, NJ), and incubated
for 7 days at 37 °C, 5% CO2. Following IL-6 treatment, MTT assays or ATP assays
were performed using the CellTiter-Glo® Luminescent Cell Viability (Promega, Madison,
WI, cat#G7571) or Vybrant® MTT Cell Proliferation (Life technologies, Carlsbad, CA,
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cat#V13154) Assay Kits, respectively. Cell viability is shown as percentage (%),
comparing mean cell viability for IL-6 treated to non-treated negative control samples.
5.13 FACS analysis. CSCs and total PCa cells were counted by FACs analysis, using
the BD LSR II (BD Biosciences, San Jose, CA, USA), at the Karmanos Cancer Institute
Microscopy, Imaging and Cytometry Resources Core. CSCs were sorted based on
triple-marker

(CD44+/CD133+/EpCAM+)

positive

status.

Fluorochrome-labeled

monoclonal antibodies against human CD44, CD133, and EpCAM proteins were
obtained from EBiosciences (San Diego, CA, USA; cat#25-0441-82), Miltenyil Biotec
(Cologne, Germany, cat#130-090-854), and BD Biosciences Franklin Lakes, NJ, USA,
cat#347198), respectively.
5.14 Stable MBD2_v2 overexpression in PCa cell lines. Packaged lentiviral particles
to overexpress GFP or mCherry control genes, or MBD2_v2 were purchased from
Cyagen Biosciences (Santa Clara, CA, USA). The custom‐synthesized human
MBD2_v2 (NM015832.4) gene, mCherry, or GFP sequence were subcloned into a
lentiviral expression vector downstream of the cytomegalovirus (CMV) promoter. The
construct was sequenced to ensure that the MBD2_v2 sequence and orientation were
correct. The expression vector also expressed a puromycin resistance gene. Cells were
transduced and selected with puromycin. GFP expression was visible by fluorescence
microscopy. Overexpression of MBD2_v2 was validated by immunoblot analysis and
semi-quantitative RT–PCR using TaqMan probes.
5.15 Meta‐analysis of MBD2_v2 expression using the Oncomine database.
Microarray data from the Oncomine database was accessed on May 22, 2017 [188]. All
PCa datasets utilizing the splice variant‐specific Affymetrix probe for MBD2_v2
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(214396_s_at) or MBD2_v1 (202484_s_at), were queried to obtain log2 mediancentered intensities, based on GS for clinical specimens only. Patient specimens (n =
244) from a total of five studies [220-224], were partitioned into two groups representing
low‐grade and high‐grade PCa (GS 4-7 and GS 8-9). A two-sided unpaired t-test was
performed on log2 median-centered intensities to compare the two groups.
5.16 Stable SRSF2 KD and MBD2_v2 overexpression in TNBC cell lines. Stable
overexpression of MBD2_v2 in MDA-MB-231 cells was performed as done by us
previously [57]. Packaged lentiviral particles to overexpress MBD2_v2 (NM015832.4)
or GFP were purchased from Cyagen Biosciences (Santa Clara, CA). Stable lentiviralmediated shRNA KD of SRSF2 expression was performed, as previously described,
using the Open Biosystems Expression Arrest GIPZ lentiviral shRNAmir system [225].
MDA-MB-468 cells were transduced with vectors targeting SRSF2 (cat#RHS443098485060 and RHS4430-101104677) or the non-silencing control vector.
5.20 Statistical analyses. Statistical analyses were performed using R 3.3.2. Graphs
were generated with R 3.3.2 or GraphPad Prism. P values ≤ 0.05 are reported as
significant.

Welch’s

t-test

was

applied

to

semi-quantitative

RT-PCR

and

mammosphere assay data. Gray’s test of difference in cumulative incidence was
used to assess the significance of differences observed in mouse tumor formation
frequency and time to event between experimental groups. Fisher’s exact test was
used to assess the difference in tumor frequency on a given date. Generalized least
squares (GLS), allowing for correlated observations in the same animal when
appropriate (i.e., bilateral inoculation) and unequal variation between titers, was used
to model log tumor mass. The P-value for the interaction between group and time
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was utilized to test whether the rate of growth, once a tumor has formed, is different
between the groups under study. Doubling time was estimated per animal using GLS
(to allow for correlated observations) and differences in estimated doubling times
between groups were assessed by Welch’s t-test.
Statistical analysis of data resulting from experiments using PCa cell lines was
performed using Graphpad Prism (GraphPad Software Inc., La Jolla, CA, USA). Semi
quantitative RT–PCR data are presented as the mean and standard deviation of a
representative experiment. Mann–Whitney U test or unpaired two‐sided t‐test (Welch's t‐
test) was performed to test the significance of difference between two groups, a P‐value
≤ 0.05 is considered to be statistically significant.
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APPENDIX
Table S1. Expression levels of MBD2 and SRSF2 transcripts in TNBC patient
tumor samples
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A

C

B

D

Figure S1. Full-length scanned images of immunoblot film. Panels here
correspond to cropped bands in: (a) Fig. 3b, (b) Fig. 4b top, (c) Fig. 4b lower, and
(d) Fig. 4c. Protein ladders were used to estimate molecular weight in kilodaltons
and are represented at the left of each panel. The antibody-targeted protein is
indicated along the right side each panel.

76
A

B

Figure S2. Testing for associations between TNBC tumor expression of
full-length MBD2 isoform MBD2_v1 and patient outcomes and BMI. (A)
Analysis was performed with the online KM Plotter database,using a logrank
test of association between relapse-free survival and MBD2_v1 transcript level.
The number of subjects at risk at different time points is indicated below the xaxis (B)Testing for transcript level associations with BMI, was done using a
separate gene expression microarray dataset generated from TNBC
specimens (n=59) collected at the Karmanos Cancer Institute, Detroit, MI,
where BMI data corresponding to deidentified samples was available. The
association between BMI and MBD2_v1expression was tested using linear
regression analysis (P>0.05, not significant).

A

B

Figure S3. MBD2_v2 expression in TNBC cell line cultures prior
to mouse inoculation. (a) Comparison of MBD2_v2 expression
levels in MDA-MB-468 and MDA-MB-231 cell cultures by semiquantitative RT-PCR, and (b) immunoblot analysis.
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Figure S4. MBD2_v2 overexpressing and GFP expressing tumor
growth curves.Growth curves for tumors formed by MBD2_v2
overexpressing and GFP expressing control MDA-MB-231 cells in
mice on the control formula diet. Tumor mass was plotted for each
tumor over the course of the 150 day experiment and modeled
growth curves (bold) are superimposed. A generalized least squares
test was used to calculate a Pvalue (P>0.05).

A

B

C

Figure S5. Effect of (–) epicatechin antioxidant treatment on ROS and MBD2_v2
levels in TNBC cell cultures. (A) The effectiveness of the (–)-epicatechin preparation to
decrease hydrogen peroxide levels were confirmed using MDA-MB-468 cells, with 48 hour
20µM treatment, and the MAK164 Intracellular hydrogen peroxide assay (Sigma-Aldrich).
Results are the mean of 3 independent experiments ± s.e.m. (B). The effect of (-)epicatechin (Epi) antioxdiant treatment (48hours,120µM) on MBD2_v2 mRNA (mean fold
change for sets of 3 technical replicates) and (C) protein expression levels in MDA-MB-468
and SUM149 TNBC cell lines. Immunoblots are representative of 2 independent
experiments for each cell line.
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B

C

Figure S6. SRSF2 knockdown tumor levels and growth curves, and patient tumor
SRSF2 expression related to BMI. (a) SRSF2 knockdown and non-silencing MDAMB-468 cell line-derived tumor growth curves. Tumor mass was plotted for each tumor
over the course of the 150 day experiment and modeled growth curves (bold) are
superimposed. A generalized least squares test was used to calculate a P value (P >0.05).
(b) SRSF2 levels in tumors formed by SRSF2 knockdown and nonsilencing vector control
MDA-MB-468 cells harvested from DIO mice (assessed by semiquantitative RTPCR
analysis). (c) Graph of patient tumor SRSF2 transcript expression and relationship with
BMI (KCI dataset). 2 of 2 translated variants (NCBI Refseq IDs) are plotted. There is no
significant association between the variables.
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B

C

Figure S7. Visceral adiposity, oxidative stress levels and enrichment of signaling pathway
genes in tumors comparing DIO and control mice. (a) Representative DIO specimen exhibiting
increased visceral adiposity relative to lean control mouse. These examples were humanly
euthanized when tumor burden end-point was reached 100 days post inoculation. (b) Liver
malondialdehyde (MDA) levels (an indicator of systemic oxidative stress) in DIO and control mice (6
randomly selected per group). (c) Tumor signaling pathways impacted by DIO. Genome-wide
expression analysis was performed to compare MDA-MB-468 tumors harvested from DIO mice
(n=3, randomly selected) with those harvested from lean control mice (n=3). The Enrichr tool and
NCI-Nature Pathways library were applied to the significant differentially expressed gene set (P <
0.01) to identify significantly over-represented signaling pathways. The P value of overlap and top
ranking Enrichment Scores, a significance value optimized for and calculated by the Enrichr tool, are
reported.
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B

Figure S8. NANOG in TNBC cell line cultures and tumors. (A) NANOG
gene expression in cultures of MBD2_v2 overexpressing MDA-MB-468 cells
compared to GFP expressing controls, by semi-quantitative RT-PCR analysis
(P<0.001,Welch’s t-test). Bars, ±s.d. for 3 technical replicates. (B)
Comparison of NANOG expression in MDA-MB-468 tumors harvested from
DIO (n=3) and control (n=3) mice by semi-quantitative RT-PCR analysis
(P<0.01,Welch’s t-test). Bars, ±s.e.m. NANOG was similarly observed to be
upregulated in tumor from DIO mice by microarray data analysis (P≤0.05,
accessible at GSE114604).
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Figure S2. Comparison ofmean values for log (base 10) FPKM read counts from RNAsequencinganalysis and mean expression values from DASL microarray analysis.Sequencing data
represents 16 PCa specimens from 8 African American (AA) men and 8 European American (EA) men, all
with Gleason score (GS)≥7(4+3). DASL gene expression data is accessible via Gene Expression Omnibus
GSE41969 and represents95 AA and 134 EA PCa specimens. The sample sets were non-overlapping and
analysis was limited to genes measured by the microarray (n=512). A test of non-parametric (Spearman)
correlation between measurementsfrom the two technologies yields a correlation of 0.805 for AA men and
0.811 for EA men.
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Figure S3. Top 9 most significant differentially expressed genes (p<0.05), based on
analysis of RNA-sequencing data from PCa and noncancer adjacent tissues as a function of
race.
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Figure S4. Additional representative images demonstrating the effect of stable MBD2_v2
overexpression in LNCaP and RC77T cells on prostasphere size relative to GFP or mCherry
expressing control cells. Bar=1,000μm
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Patient No.

Race

Grade

1

AA

8

2

AA

8

3

AA

9

4

AA

9

5

AA

8

6

AA

9

7

AA

8

8

AA

8

9

C

7 (4+3)

10

C

7 (4+3)

11

C

7 (4+3)

12

C

7 (4+3)

13

C

8

14

C

8

15

C

7 (4+3)

16

C

7 (4+3)

Supplementary Table S1. Gleason Score/Grade for each PCa sample used
in RNA-sequencing analysis. RNA sequencing was performed on matched
high grade [GS≥7(4+3)] prostate tumor and adjacent nonmalignant specimens
from 16 patients (8 AAM and 8 EAM.
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Supplementary Table S2. The Enrichr tool was used to identify significantly over-represented
KEGG pathways in the results of RNA-sequencing data differential analysis comparing tumor
versus normal gene expression as a function of race. Genes from our analyzed dataset that are
within each significant pathway are listed, including cytokines IL6 and TGFB1.
KEGG Pathway

Cytokine-cytokine receptor
interaction_Homo
sapiens_hsa04060

Overlap

29/265

P-value

Genes from analyzed dataset in pathway

0.003

CNTF;CD40;IFNA7;IFNA1;IL26;FLT3;IL23R;PDGFB;IL1
8RAP;CCR8;TNFRSF17;IL12A;PDGFRB;
PDGFRA;XCR1;TGFB1;CCL21;IL11RA;TNFRSF18;FLT
3LG;INHBB;TNFRSF1B;IL6;IL23A;XCL1;
TNFRSF25;IL7R;TNFRSF21;IL9R

Neuroactive ligand-receptor
interaction_Homo
sapiens_hsa04080

27/277

0.020

PTGFR;RXFP4;PLG;HTR2A;GRPR;RXFP2;GRM1;GR
M3;GHRHR;HRH1;CCKAR;NPBWR2;DRD2;GRIA3;NT
SR2;GABRA2;UTS2R;CHRNB4;TAAR8;GCGR;GABRA
3;TACR1;GRIN2C;HCRTR2; P2RX2;MC5R;F2RL3

Inflammatory bowel disease
(IBD)_Homo
sapiens_hsa05321

9/65

0.022

SMAD2;IL6;TGFB1;IL18RAP;IL23A;IL23R;IL12A;FOXP
3;HLA-DPA1

0.022

PDGFRB;PRKCG;PDGFRA;PTGFR;ATP2B3;TACR1;H
TR2A;ATP2B1;GRIN2C;CACNA1F;GRPR;
GRM1;SLC8A2;HRH1;PPP3CC;CCKAR;P2RX2;PLCG2
;CACNA1S

0.035

FLT3;PDGFB;LAMC2;HIF1A;ETS1;ADCY5;FGF4;FGF5
;FGF6;WNT11;CASP8;PLCG2;VHL;WNT1;PRKCG;PD
GFRB;SMAD2;STAT5B;PDGFRA;EGLN2;TGFB1;LAM
B2;FLT3LG;GNG12;IL6;CDK6;
RAD51;CCNE1;COL4A3;COL4A6;RARB;COL4A5;ITGA
6;FGF12;F2RL3

Calcium signaling
pathway_Homo
sapiens_hsa04020

Pathways in cancer_Homo
sapiens_hsa05200

19/180

35/397
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Supplementary Table S3. FACS data collected for IL6-treated and non-treated PCa cell lines
with sorting of the cancer stem-like cell fraction based on positive status of three surface
markers, CD44, CD133, and EPCAM. Based on analysis of 3 independent replicates, the
values under the Mean Percentage (%) column represent the triple marker-positive cell
population fraction of the mean total live cell count. For each cell line, fold-change represents
the percentage of triple marker positive cells in IL6 treated cultures relative to the percentage in
the vehicle control condition. SEM, standard error of mean.
PCa Cell
Line

LNCaP

RC77T

PC3

DU-145

Sample
Treatment

Mean Total
Cell Count

Mean %
single/live cells
CD44+/CD133+/EPCAM+

FoldChange

SEM

p-value

IL6

519923

3.718

3.3

0.5115

0.02

Control

1054734

1.132

1.0

0.2710

IL6

505971

0.012

2.5

0.0015

Control

671333

0.005

1.0

0.0007

IL6

490014

0.059

1.6

0.0238

Control

449287

0.037

1.0

0.0144

IL6

600000

0.029

1.1

0.0087

Control

612667

0.026

1.0

0.0072

0.02
0.93
0.97
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Obesity is a risk factor for both TNBC and PCa, and pro-inflammatory
features associated with obesity, including upregulated production of ROS,
promote CSCs. Previously published work from the Bollig-Fischer laboratory
established that TNBC CSCs could be inhibited by neutralizing ROS in culture
with H2O2 targeted antioxidants. In this report, antioxidant treatment resulted in
the downregulation of mRNA splicing variant MBD2_v2. MBD2_v2 was highly
expressed in CSCs versus bulk TNBC cells and supported self-renewal in vitro.
As obesity is coupled with increased ROS, we hypothesized that obesity
could drive CSCs via MBD2_v2 expression. The work presented in this thesis
addressed this hypothesis, linking MBD2_v2 expression to obesity in TNBC
patients, and demonstrating the importance of SRSF2-MBD2_v2 mediated
expression of pluripotency transcription factors in driving tumor-initiating TNBC
CSCs via DIO and PCa CSCs via STAT3-dependent IL-6 signaling.
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